WO2016194685A1 - アルミニウムを含有するアジュバント組成物およびこれを含むワクチン組成物 - Google Patents
アルミニウムを含有するアジュバント組成物およびこれを含むワクチン組成物 Download PDFInfo
- Publication number
- WO2016194685A1 WO2016194685A1 PCT/JP2016/065216 JP2016065216W WO2016194685A1 WO 2016194685 A1 WO2016194685 A1 WO 2016194685A1 JP 2016065216 W JP2016065216 W JP 2016065216W WO 2016194685 A1 WO2016194685 A1 WO 2016194685A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- antigen
- sensitive
- aluminum
- alum
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 216
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 title claims abstract description 115
- 239000002671 adjuvant Substances 0.000 title claims abstract description 114
- 229910052782 aluminium Inorganic materials 0.000 title claims abstract description 112
- 229960005486 vaccine Drugs 0.000 title claims description 79
- 239000000126 substance Substances 0.000 claims abstract description 210
- 239000000427 antigen Substances 0.000 claims description 222
- 108091007433 antigens Proteins 0.000 claims description 222
- 102000036639 antigens Human genes 0.000 claims description 222
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 110
- 150000001875 compounds Chemical class 0.000 claims description 108
- 229960003964 deoxycholic acid Drugs 0.000 claims description 97
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical group C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 94
- -1 sorbitan fatty acid ester Chemical class 0.000 claims description 68
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims description 66
- 239000012528 membrane Substances 0.000 claims description 65
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 claims description 53
- 230000001737 promoting effect Effects 0.000 claims description 53
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 49
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 claims description 48
- 229960001661 ursodiol Drugs 0.000 claims description 48
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 45
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims description 43
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 43
- 239000001685 glycyrrhizic acid Substances 0.000 claims description 43
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 43
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 43
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 43
- 125000002252 acyl group Chemical group 0.000 claims description 41
- 125000004432 carbon atom Chemical group C* 0.000 claims description 41
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 40
- 238000002156 mixing Methods 0.000 claims description 35
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 33
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 30
- 239000004359 castor oil Substances 0.000 claims description 30
- 235000019438 castor oil Nutrition 0.000 claims description 30
- 230000006378 damage Effects 0.000 claims description 30
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 30
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 29
- 239000002253 acid Substances 0.000 claims description 28
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims description 24
- 239000000194 fatty acid Substances 0.000 claims description 24
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 23
- 229930195729 fatty acid Natural products 0.000 claims description 23
- 150000002148 esters Chemical class 0.000 claims description 20
- 229960000984 tocofersolan Drugs 0.000 claims description 20
- OQQOAWVKVDAJOI-UHFFFAOYSA-N (2-dodecanoyloxy-3-hydroxypropyl) dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCC OQQOAWVKVDAJOI-UHFFFAOYSA-N 0.000 claims description 19
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 claims description 19
- 229940087168 alpha tocopherol Drugs 0.000 claims description 19
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 claims description 19
- 235000004835 α-tocopherol Nutrition 0.000 claims description 19
- 239000002076 α-tocopherol Substances 0.000 claims description 19
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 claims description 18
- 229960001091 chenodeoxycholic acid Drugs 0.000 claims description 18
- 239000003613 bile acid Substances 0.000 claims description 17
- UHUSDOQQWJGJQS-UHFFFAOYSA-N glycerol 1,2-dioctadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCC UHUSDOQQWJGJQS-UHFFFAOYSA-N 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 17
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims description 16
- AFSHUZFNMVJNKX-UHFFFAOYSA-N 1,2-di-(9Z-octadecenoyl)glycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCC=CCCCCCCCC AFSHUZFNMVJNKX-UHFFFAOYSA-N 0.000 claims description 16
- AFSHUZFNMVJNKX-LLWMBOQKSA-N 1,2-dioleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCC\C=C/CCCCCCCC AFSHUZFNMVJNKX-LLWMBOQKSA-N 0.000 claims description 16
- 239000004380 Cholic acid Substances 0.000 claims description 16
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 16
- 235000019416 cholic acid Nutrition 0.000 claims description 16
- 229960002471 cholic acid Drugs 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- DGABKXLVXPYZII-UHFFFAOYSA-N Hyodeoxycholic acid Natural products C1C(O)C2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 DGABKXLVXPYZII-UHFFFAOYSA-N 0.000 claims description 15
- DGABKXLVXPYZII-SIBKNCMHSA-N hyodeoxycholic acid Chemical compound C([C@H]1[C@@H](O)C2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 DGABKXLVXPYZII-SIBKNCMHSA-N 0.000 claims description 15
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 15
- 108010035713 Glycodeoxycholic Acid Proteins 0.000 claims description 14
- WVULKSPCQVQLCU-UHFFFAOYSA-N Glycodeoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 WVULKSPCQVQLCU-UHFFFAOYSA-N 0.000 claims description 14
- WVULKSPCQVQLCU-BUXLTGKBSA-N glycodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 WVULKSPCQVQLCU-BUXLTGKBSA-N 0.000 claims description 14
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 claims description 12
- 229960003720 enoxolone Drugs 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 abstract description 12
- 230000024932 T cell mediated immunity Effects 0.000 abstract description 2
- 229940037003 alum Drugs 0.000 description 177
- 239000007864 aqueous solution Substances 0.000 description 96
- 230000007969 cellular immunity Effects 0.000 description 68
- 239000006185 dispersion Substances 0.000 description 57
- 239000000243 solution Substances 0.000 description 57
- FVXDQWZBHIXIEJ-LNDKUQBDSA-N 1,2-di-[(9Z,12Z)-octadecadienoyl]-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC FVXDQWZBHIXIEJ-LNDKUQBDSA-N 0.000 description 52
- 238000000034 method Methods 0.000 description 50
- 210000004027 cell Anatomy 0.000 description 43
- 230000000694 effects Effects 0.000 description 41
- 230000034217 membrane fusion Effects 0.000 description 34
- 238000011156 evaluation Methods 0.000 description 32
- 239000000872 buffer Substances 0.000 description 28
- 239000002953 phosphate buffered saline Substances 0.000 description 28
- 238000010828 elution Methods 0.000 description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 238000007922 dissolution test Methods 0.000 description 23
- 230000006698 induction Effects 0.000 description 23
- 239000002502 liposome Substances 0.000 description 21
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- 230000015788 innate immune response Effects 0.000 description 18
- 230000001580 bacterial effect Effects 0.000 description 17
- 230000004727 humoral immunity Effects 0.000 description 17
- 230000001939 inductive effect Effects 0.000 description 17
- 239000002904 solvent Substances 0.000 description 17
- 210000001163 endosome Anatomy 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 239000010409 thin film Substances 0.000 description 16
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 15
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 15
- 229920000053 polysorbate 80 Polymers 0.000 description 15
- 238000007920 subcutaneous administration Methods 0.000 description 15
- 101000609767 Dromaius novaehollandiae Ovalbumin Proteins 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- 229920001213 Polysorbate 20 Polymers 0.000 description 14
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 14
- 239000007788 liquid Substances 0.000 description 14
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 14
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 13
- 230000001086 cytosolic effect Effects 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- MLKLDGSYMHFAOC-AREMUKBSSA-N 1,2-dicapryl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCC MLKLDGSYMHFAOC-AREMUKBSSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 12
- 210000001744 T-lymphocyte Anatomy 0.000 description 12
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 230000004927 fusion Effects 0.000 description 12
- 239000002245 particle Substances 0.000 description 12
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 11
- 239000012979 RPMI medium Substances 0.000 description 11
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 11
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 11
- 238000010586 diagram Methods 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 229920000136 polysorbate Polymers 0.000 description 11
- 235000011078 sorbitan tristearate Nutrition 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 229930003799 tocopherol Natural products 0.000 description 11
- 239000011732 tocopherol Substances 0.000 description 11
- 229940042585 tocopherol acetate Drugs 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 10
- 238000004090 dissolution Methods 0.000 description 10
- 239000003995 emulsifying agent Substances 0.000 description 10
- 230000002209 hydrophobic effect Effects 0.000 description 10
- 229960001295 tocopherol Drugs 0.000 description 10
- 235000010384 tocopherol Nutrition 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 9
- 239000003125 aqueous solvent Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 210000000612 antigen-presenting cell Anatomy 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 150000004665 fatty acids Chemical class 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 239000007987 MES buffer Substances 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 210000004443 dendritic cell Anatomy 0.000 description 6
- 230000002538 fungal effect Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000001593 sorbitan monooleate Substances 0.000 description 6
- 229940035049 sorbitan monooleate Drugs 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- 239000004147 Sorbitan trioleate Substances 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 239000010408 film Substances 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 229960005150 glycerol Drugs 0.000 description 5
- 238000001507 sample dispersion Methods 0.000 description 5
- 238000007086 side reaction Methods 0.000 description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
- 235000011069 sorbitan monooleate Nutrition 0.000 description 5
- 235000019337 sorbitan trioleate Nutrition 0.000 description 5
- 229960000391 sorbitan trioleate Drugs 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 210000000605 viral structure Anatomy 0.000 description 5
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 4
- KUVAEMGNHJQSMH-UHFFFAOYSA-N (3-dodecanoyloxy-2-hydroxypropyl) dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCC KUVAEMGNHJQSMH-UHFFFAOYSA-N 0.000 description 4
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 108010033276 Peptide Fragments Proteins 0.000 description 4
- 102000007079 Peptide Fragments Human genes 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 210000004681 ovum Anatomy 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
- KXXXUIKPSVVSAW-UHFFFAOYSA-K pyranine Chemical compound [Na+].[Na+].[Na+].C1=C2C(O)=CC(S([O-])(=O)=O)=C(C=C3)C2=C2C3=C(S([O-])(=O)=O)C=C(S([O-])(=O)=O)C2=C1 KXXXUIKPSVVSAW-UHFFFAOYSA-K 0.000 description 4
- 230000008707 rearrangement Effects 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 3
- 102100027211 Albumin Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 102000043131 MHC class II family Human genes 0.000 description 3
- 108091054438 MHC class II family Proteins 0.000 description 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 101001044384 Mus musculus Interferon gamma Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108010075205 OVA-8 Proteins 0.000 description 3
- 206010043376 Tetanus Diseases 0.000 description 3
- 206010052779 Transplant rejections Diseases 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 101710123661 Venom allergen 5 Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- NVANJYGRGNEULT-BDZGGURLSA-N [(3s,4r,5r)-4-hexadecanoyloxy-5-[(1r)-1-hexadecanoyloxy-2-hydroxyethyl]oxolan-3-yl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@H](CO)[C@H]1OC[C@H](OC(=O)CCCCCCCCCCCCCCC)[C@H]1OC(=O)CCCCCCCCCCCCCCC NVANJYGRGNEULT-BDZGGURLSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 229940107161 cholesterol Drugs 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 238000012136 culture method Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 206010013023 diphtheria Diseases 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 3
- 239000001589 sorbitan tristearate Substances 0.000 description 3
- 229960004129 sorbitan tristearate Drugs 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- IJFVSSZAOYLHEE-SSEXGKCCSA-N 1,2-dilauroyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCC IJFVSSZAOYLHEE-SSEXGKCCSA-N 0.000 description 2
- QHZLMUACJMDIAE-UHFFFAOYSA-N 1-monopalmitoylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)CO QHZLMUACJMDIAE-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IJFVSSZAOYLHEE-UHFFFAOYSA-N 2,3-di(dodecanoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCC IJFVSSZAOYLHEE-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010004593 Bile duct cancer Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 241000218645 Cedrus Species 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000010956 Glypican Human genes 0.000 description 2
- 108050001154 Glypican Proteins 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 2
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010023825 Laryngeal cancer Diseases 0.000 description 2
- 206010062038 Lip neoplasm Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 208000032271 Malignant tumor of penis Diseases 0.000 description 2
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 2
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 2
- 108010008707 Mucin-1 Proteins 0.000 description 2
- 102100034256 Mucin-1 Human genes 0.000 description 2
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 208000002471 Penile Neoplasms Diseases 0.000 description 2
- 206010034299 Penile cancer Diseases 0.000 description 2
- 201000005702 Pertussis Diseases 0.000 description 2
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 2
- 206010034811 Pharyngeal cancer Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 241000702670 Rotavirus Species 0.000 description 2
- 235000002597 Solanum melongena Nutrition 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 206010057644 Testis cancer Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 208000026900 bile duct neoplasm Diseases 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000002619 cancer immunotherapy Methods 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 239000012645 endogenous antigen Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- XIRNKXNNONJFQO-UHFFFAOYSA-N ethyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC XIRNKXNNONJFQO-UHFFFAOYSA-N 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- MMKRHZKQPFCLLS-UHFFFAOYSA-N ethyl myristate Chemical compound CCCCCCCCCCCCCC(=O)OCC MMKRHZKQPFCLLS-UHFFFAOYSA-N 0.000 description 2
- MVLVMROFTAUDAG-UHFFFAOYSA-N ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC MVLVMROFTAUDAG-UHFFFAOYSA-N 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 201000010175 gallbladder cancer Diseases 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000007986 glycine-NaOH buffer Substances 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- BTFJIXJJCSYFAL-UHFFFAOYSA-N icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 201000006721 lip cancer Diseases 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- UQDUPQYQJKYHQI-UHFFFAOYSA-N methyl laurate Chemical compound CCCCCCCCCCCC(=O)OC UQDUPQYQJKYHQI-UHFFFAOYSA-N 0.000 description 2
- JGHZJRVDZXSNKQ-UHFFFAOYSA-N methyl octanoate Chemical compound CCCCCCCC(=O)OC JGHZJRVDZXSNKQ-UHFFFAOYSA-N 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 229940105132 myristate Drugs 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 201000011682 nervous system cancer Diseases 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 2
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- ZNJHFNUEQDVFCJ-UHFFFAOYSA-M sodium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[Na+].OCCN1CCN(CCS(O)(=O)=O)CC1 ZNJHFNUEQDVFCJ-UHFFFAOYSA-M 0.000 description 2
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 2
- 239000001570 sorbitan monopalmitate Substances 0.000 description 2
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 2
- 235000011076 sorbitan monostearate Nutrition 0.000 description 2
- 239000001587 sorbitan monostearate Substances 0.000 description 2
- 229940035048 sorbitan monostearate Drugs 0.000 description 2
- 229950003429 sorbitan palmitate Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 206010046885 vaginal cancer Diseases 0.000 description 2
- 208000013139 vaginal neoplasm Diseases 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- DRAWQKGUORNASA-UHFFFAOYSA-N (2-hydroxy-3-octadec-9-enoyloxypropyl) octadec-9-enoate Chemical compound CCCCCCCCC=CCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCC=CCCCCCCCC DRAWQKGUORNASA-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- ZQBULZYTDGUSSK-UHFFFAOYSA-N (3-hydroxy-2-octanoyloxypropyl) octanoate Chemical compound CCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCC ZQBULZYTDGUSSK-UHFFFAOYSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- JFBCSFJKETUREV-UHFFFAOYSA-N 1,2 ditetradecanoylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCC JFBCSFJKETUREV-UHFFFAOYSA-N 0.000 description 1
- GNSDEDOVXZDMKM-UHFFFAOYSA-N 1,2-didecanoylglycerol Chemical compound CCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCC GNSDEDOVXZDMKM-UHFFFAOYSA-N 0.000 description 1
- GFAZGHREJPXDMH-UHFFFAOYSA-N 1,3-dipalmitoylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCC GFAZGHREJPXDMH-UHFFFAOYSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 description 1
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 1
- 150000000215 1-octanols Chemical class 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- ANPSOVQQJHCXHU-KVVVOXFISA-N 2,3-dihydroxypropyl (z)-octadec-9-enoate;propane-1,2,3-triol Chemical class OCC(O)CO.CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO ANPSOVQQJHCXHU-KVVVOXFISA-N 0.000 description 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- HEBDGRTWECSNNT-UHFFFAOYSA-N 2-methylidenepentanoic acid Chemical compound CCCC(=C)C(O)=O HEBDGRTWECSNNT-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- SMKBSSHVLHIPLU-UHFFFAOYSA-N 3-acridin-10-ium-10-ylpropane-1-sulfonate Chemical compound C1=CC=C2[N+](CCCS(=O)(=O)[O-])=C(C=CC=C3)C3=CC2=C1 SMKBSSHVLHIPLU-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 229910017119 AlPO Inorganic materials 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 101100446590 Arabidopsis thaliana FIM5 gene Proteins 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 229920001342 Bakelite® Polymers 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 238000011814 C57BL/6N mouse Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- LKUNXBRZDFMZOK-GFCCVEGCSA-N Capric acid monoglyceride Natural products CCCCCCCCCC(=O)OC[C@H](O)CO LKUNXBRZDFMZOK-GFCCVEGCSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 208000019872 Drug Eruptions Diseases 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 1
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 1
- 101150106011 FIM2 gene Proteins 0.000 description 1
- 101150048576 FIM3 gene Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 101710113436 GTPase KRas Proteins 0.000 description 1
- 102100039788 GTPase NRas Human genes 0.000 description 1
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 1
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000006173 Good's buffer Substances 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 241000228402 Histoplasma Species 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101001073409 Homo sapiens Retrotransposon-derived protein PEG10 Proteins 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- ARIWANIATODDMH-UHFFFAOYSA-N Lauric acid monoglyceride Natural products CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241000209082 Lolium Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 102000047918 Myelin Basic Human genes 0.000 description 1
- 102000055324 Myelin Proteolipid Human genes 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- 101710094913 Myelin proteolipid protein Proteins 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- MXRIRQGCELJRSN-UHFFFAOYSA-N O.O.O.[Al] Chemical compound O.O.O.[Al] MXRIRQGCELJRSN-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000713112 Orthobunyavirus Species 0.000 description 1
- 241000150452 Orthohantavirus Species 0.000 description 1
- 229920006197 POE laurate Polymers 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241000282322 Panthera Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100032709 Potassium-transporting ATPase alpha chain 2 Human genes 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 101710192141 Protein Nef Proteins 0.000 description 1
- 108010083204 Proton Pumps Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 206010037075 Protozoal infections Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 102100035844 Retrotransposon-derived protein PEG10 Human genes 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 241000606651 Rickettsiales Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 101710137302 Surface antigen S Proteins 0.000 description 1
- 239000007994 TES buffer Substances 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 208000006288 Vascular Tissue Neoplasms Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- HTNVOHCAVLCTOK-PMGAGZRRSA-N [1-hydroxy-3-[(Z)-octadec-9-enoyl]oxypropan-2-yl] (Z)-20,21-dihydroxyhenicos-9-enoate Chemical compound C(C(O)CO)CCCCCCCC\C=C/CCCCCCCC(=O)OC(COC(CCCCCCC\C=C/CCCCCCCC)=O)CO HTNVOHCAVLCTOK-PMGAGZRRSA-N 0.000 description 1
- ZXRRHFSTAFVGOC-UHFFFAOYSA-N [AlH3].[K] Chemical compound [AlH3].[K] ZXRRHFSTAFVGOC-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 235000010210 aluminium Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 208000005980 beta thalassemia Diseases 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- 108091022863 bile acid binding Proteins 0.000 description 1
- 102000030904 bile acid binding Human genes 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 208000029185 blood vessel neoplasm Diseases 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000003374 diacylglycerol group Chemical group 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- HBEDSQVIWPRPAY-UHFFFAOYSA-N dihydro-benzofuran Natural products C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- UZUODNWWWUQRIR-UHFFFAOYSA-L disodium;3-aminonaphthalene-1,5-disulfonate Chemical compound [Na+].[Na+].C1=CC=C(S([O-])(=O)=O)C2=CC(N)=CC(S([O-])(=O)=O)=C21 UZUODNWWWUQRIR-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- QYDYPVFESGNLHU-UHFFFAOYSA-N elaidic acid methyl ester Natural products CCCCCCCCC=CCCCCCCCC(=O)OC QYDYPVFESGNLHU-UHFFFAOYSA-N 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 101150030339 env gene Proteins 0.000 description 1
- YYZUSRORWSJGET-UHFFFAOYSA-N ethyl octanoate Chemical compound CCCCCCCC(=O)OCC YYZUSRORWSJGET-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229940067592 ethyl palmitate Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000003619 fibrillary effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 101150098622 gag gene Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- JEJLGIQLPYYGEE-UHFFFAOYSA-N glycerol dipalmitate Natural products CCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCC JEJLGIQLPYYGEE-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 229940074049 glyceryl dilaurate Drugs 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940074774 glycyrrhizinate Drugs 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000045108 human EGFR Human genes 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- SXQCTESRRZBPHJ-UHFFFAOYSA-M lissamine rhodamine Chemical compound [Na+].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O SXQCTESRRZBPHJ-UHFFFAOYSA-M 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- QYDYPVFESGNLHU-KHPPLWFESA-N methyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC QYDYPVFESGNLHU-KHPPLWFESA-N 0.000 description 1
- 229940073769 methyl oleate Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 150000002759 monoacylglycerols Chemical class 0.000 description 1
- 229940074096 monoolein Drugs 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- OFWOMCSHJWTBGF-UHFFFAOYSA-N name was omitted Natural products CC(C)=CCCC(O)(CO)C=C OFWOMCSHJWTBGF-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- UIRLPEMNFBJPIT-UHFFFAOYSA-N odn 2395 Chemical compound O=C1NC(=O)C(C)=CN1C1OC(COP(O)(O)=O)C(OP(O)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)C1 UIRLPEMNFBJPIT-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 102000007863 pattern recognition receptors Human genes 0.000 description 1
- 108010089193 pattern recognition receptors Proteins 0.000 description 1
- 108010021711 pertactin Proteins 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 101150088264 pol gene Proteins 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- JCMLLSQFQWFWDS-UHFFFAOYSA-N pyridin-1-ium;1,4-xylene;dibromide Chemical compound [Br-].[Br-].C1=CC=[NH+]C=C1.C1=CC=[NH+]C=C1.CC1=CC=C(C)C=C1 JCMLLSQFQWFWDS-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- LKUNXBRZDFMZOK-UHFFFAOYSA-N rac-1-monodecanoylglycerol Chemical compound CCCCCCCCCC(=O)OCC(O)CO LKUNXBRZDFMZOK-UHFFFAOYSA-N 0.000 description 1
- DCBSHORRWZKAKO-UHFFFAOYSA-N rac-1-monomyristoylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(O)CO DCBSHORRWZKAKO-UHFFFAOYSA-N 0.000 description 1
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 1
- 239000009342 ragweed pollen Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- IRHWMYKYLWNHTL-UHFFFAOYSA-M sodium 2-(N-morpholino)ethanesulfonate Chemical compound [Na+].[O-]S(=O)(=O)CCN1CCOCC1 IRHWMYKYLWNHTL-UHFFFAOYSA-M 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- VMSNAUAEKXEYGP-YEUHZSMFSA-M sodium glycodeoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 VMSNAUAEKXEYGP-YEUHZSMFSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- WDFRNBJHDMUMBL-FUXQPCDDSA-M sodium;(4r)-4-[(3r,5s,7s,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoate Chemical compound [Na+].C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)CC1 WDFRNBJHDMUMBL-FUXQPCDDSA-M 0.000 description 1
- ZEDAGFBWUVYFQU-UHFFFAOYSA-M sodium;3-morpholin-4-ylpropane-1-sulfonate;hydrate Chemical compound [OH-].[Na+].OS(=O)(=O)CCCN1CCOCC1 ZEDAGFBWUVYFQU-UHFFFAOYSA-M 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- MAYCICSNZYXLHB-UHFFFAOYSA-N tricaproin Chemical compound CCCCCC(=O)OCC(OC(=O)CCCCC)COC(=O)CCCCC MAYCICSNZYXLHB-UHFFFAOYSA-N 0.000 description 1
- 229940093609 tricaprylin Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 201000011531 vascular cancer Diseases 0.000 description 1
- 206010055031 vascular neoplasm Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Definitions
- the present invention relates to an adjuvant composition containing aluminum and a vaccine composition containing the same.
- the immune system is a defense mechanism that protects the living body from diseases and the like by eliminating foreign substances and abnormal cells that have entered the living body.
- An adjuvant is a substance used for enhancing the effect of a vaccine.
- the function of the immune system is generally expressed through two mechanisms, humoral immunity and cellular immunity.
- Humoral immunity is a mechanism centered on components that are dissolved in serum such as antibodies and complement.
- Antibody induction is important from a vaccine perspective and is usually expressed as follows. That is, exogenous antigens such as bacteria that have entered the living body are taken into antigen-presenting cells by endocytosis, digested by proteolytic enzymes in endosomes in the antigen-presenting cells, and decomposed into peptide fragments. The peptide fragment binds to a major histocompatibility complex (MHC) class II molecule, and the resulting complex is presented to CD4-positive T cells on the surface of antigen-presenting cells, which activates CD4-positive T cells.
- MHC major histocompatibility complex
- the activated CD4 positive T cells release cytokines and the like, so that antibodies are finally produced from the B cells.
- the MHC class II molecule is expressed on macrophages, dendritic cells, activated T cells, B cells and the like.
- materials containing aluminum have an old history and are widely used throughout the world. Examples thereof include aluminum hydroxide, aluminum phosphate, potassium aluminum sulfate (alum), aluminum chloride, and the like, and these are sometimes simply referred to as alum.
- cellular immunity is a mechanism centered on cells responsible for foreign body exclusion such as macrophages, cytotoxic T cells (CTL), natural killer cells, and the like.
- CTL cytotoxic T cells
- Induction of cell-mediated immunity can attract virus-infected cells, cancer cells, and the like, and thus has attracted much attention from the viewpoint of treatment by immunity.
- CTL induction is expected to be realized from application to cancer immunotherapy. Induction of CTL is usually expressed as follows. That is, endogenous antigens such as proteins produced in virus-infected cells and cancer cells are ubiquitinated and then decomposed into peptides by the proteasome.
- the decomposed peptide binds to MHC class I molecules, and the resulting complex is presented to CD8 positive T cells on the surface of antigen presenting cells, thereby activating CD8 positive T cells. Then, activated CD8-positive T cells are differentiated into cytotoxic T cells (CTL).
- CTL cytotoxic T cells
- the MHC class I molecule is present on the surface of almost all nucleated cells and platelets.
- an object of the present invention is to provide an adjuvant that is highly safe and that effectively induces cellular immunity through cross-presentation.
- the present inventor conducted extensive research. As a result, a substance that contains aluminum is used in combination with a carrier that is sensitive to pH as a substance having a stimulus that activates innate immunity (hereinafter also referred to simply as “a substance that activates innate immunity”). Thus, the present inventors have found that the above problems can be solved, and have completed the present invention.
- an adjuvant composition comprising a pH-sensitive carrier and a substance containing aluminum; (2) The adjuvant composition according to (1), wherein the substance containing aluminum is at least one selected from the group consisting of aluminum hydroxide and aluminum phosphate; (3)
- the pH sensitive carrier is a group consisting of deoxycholic acid, cholic acid, ursodeoxycholic acid, chenodeoxycholic acid, hyodeoxycholic acid, higher bile acids, glycodeoxycholic acid, glycyrrhizic acid, glycyrrhetinic acid and salts thereof
- At least one pH sensitive compound selected from: Phosphatidylcholine having only an acyl group having 10 to 12 carbon atoms, polyoxyethylene sorbitan monofatty acid ester having an acyl group having 12 to 18 carbon atoms, sorbitan fatty acid ester having only an acyl group having 16 to 18 carbon atoms, glycerol monooleate
- FIG. 1 is a schematic diagram of an adjuvant composition according to one embodiment of the present invention and a vaccine composition containing the same.
- FIG. 2 is a diagram showing the results of evaluating the induction of cellular immunity (CTL) by the ELIspot method of a vaccine composition and a comparative sample (composition). Cells that produced IFN ⁇ in response to SIINFEKL, an MHC class I-restricted peptide, were detected by spot formation.
- CTL cellular immunity
- A is antigen only
- B is a mixture of antigen and tocopherol
- C is a mixture of antigen and tocopherol acetate
- D is a mixture of antigen and alum
- E is an antigen, tocopherol and pH.
- FIG. 3 is a diagram showing the results of comparison with CpG-ODN and evaluation of antigen specificity of induced cellular immunity by ELIspot method.
- A) is a mixture of antigen and alum
- B) is a mixture of antigen, alum and pH sensitive carrier
- C) is a mixture of antigen and CpG-ODN, and immunized with the composition obtained It is a result.
- FIG. 4 is a diagram showing the results of examining the amount of alum required to induce cellular immunity by the ELIspot method.
- the pH-sensitive carrier was a complex of 100 nmol DLPC and 160 nmol deoxycholic acid, and alum was aluminum hydroxide.
- (A) is antigen only
- (B) is a mixture of antigen and 10 ⁇ g alum
- (C) is a mixture of antigen, 100 ⁇ g alum and pH sensitive carrier
- (D) is an antigen, 10 ⁇ g alum and pH sensitive carrier.
- E) is a mixture of an antigen and 1 ⁇ g of alum and a pH-sensitive carrier
- (F) is a mixture of the antigen, 0.1 ⁇ g of alum and a pH-sensitive carrier
- Is the result of FIG. 5 is a graph showing the results of examining the amount of pH-sensitive carrier necessary for inducing cellular immunity by the ELIspot method.
- the pH-sensitive carrier was based on a complex of 100 nmol DLPC and 160 nmol deoxycholic acid, and the complex was diluted to a predetermined concentration and used for each evaluation.
- (A) is antigen only
- (B) is a mixture of antigen and alum
- (C) is a mixture of antigen, alum and pH sensitive carrier
- (D) is an antigen and alum, a pH sensitive carrier diluted 10-fold.
- E) is a composition obtained by mixing an antigen and alum with a pH-sensitive carrier diluted 100-fold
- (F) is a composition obtained by mixing an antigen, alum and a pH-sensitive carrier diluted 1000-fold. It is the result when immunized.
- FIG. 6 is a diagram showing the results of verifying induction of humoral immunity by the combined use of alum and a pH-sensitive carrier. Induction of humoral immunity was evaluated by IgG antibody titer.
- FIG. 7 is a diagram showing the results of examining the types of alum suitable as components of a vaccine composition for inducing cellular immunity by the ELIspot method.
- the pH-sensitive carrier was a complex of 100 nmol DLPC and 160 nmol deoxycholic acid, and alum was aluminum hydroxide.
- (A) is a mixture of antigen and 10 ⁇ g of aluminum phosphate
- (B) is a mixture of antigen, 1 ⁇ g of aluminum phosphate and pH sensitive carrier
- (C) is a pH sensitive of antigen, 0.1 ⁇ g of aluminum phosphate and pH.
- (D) is a mixture of antigen and 10 ⁇ g of potassium aluminum sulfate
- (E) is a mixture of antigen, 1 ⁇ g of potassium aluminum sulfate and pH sensitive carrier
- (F) is a mixture of antigen and 0.1 ⁇ g of sulfate. It is a result at the time of immunizing with the composition obtained by mixing potassium aluminum and a pH sensitive carrier.
- FIG. 8 is a diagram showing the results of evaluating the influence of alum on the membrane destruction function promoting effect of alum when alum and a pH-sensitive carrier are mixed.
- (A) is the type of alum
- (B) is the result of evaluation regarding the amount of alum.
- FIG. 9 is a diagram showing the results of examining the influence of alum on the membrane fusion function promoting effect of the pH-sensitive carrier.
- FIG. 10 is a diagram showing the results of evaluating the influence of alum on the membrane destruction function promoting effect of alum when the composition of the pH-sensitive carrier, in particular, the amount of deoxycholic acid is changed.
- FIG. 11 is a diagram showing the results of evaluating the induction of cellular immunity by the vaccine composition by the ELIspot method in the intradermal administration route.
- the pH-sensitive carrier was a complex of 100 nmol DLPC and 160 nmol deoxycholic acid, and alum was aluminum hydroxide.
- (A) is a result of subcutaneous administration of a composition in which an antigen and alum are mixed
- (B) is a result of subcutaneous administration of a composition in which an antigen, alum and a pH-sensitive carrier are mixed.
- D) is the result of intradermal administration of a composition in which an antigen, alum and a pH-sensitive carrier are mixed.
- (E) to (H) are evaluations of antigen specificity, and are attempts to form a spot without adding SIINFEKL peptide.
- (E) is a result of subcutaneous administration of a composition in which an antigen and alum are mixed
- (F) is a result of subcutaneous administration of a composition in which an antigen, alum and a pH-sensitive carrier are mixed.
- H is the result of intradermal administration of a composition in which an antigen, alum and a pH-sensitive carrier are mixed.
- an adjuvant composition comprising a pH sensitive carrier and a substance containing aluminum.
- the adjuvant composition provides an adjuvant capable of effectively inducing cellular immunity through cross presentation.
- the adjuvant composition provides a highly safe adjuvant.
- the adjuvant composition according to this embodiment includes a pH-sensitive carrier (hereinafter sometimes simply referred to as “carrier”, “aggregate”, or “complex”) and a substance containing aluminum. That is, the adjuvant composition of this embodiment includes a substance containing aluminum as a substance having a stimulus that activates innate immunity (a substance that activates innate immunity).
- the adjuvant composition according to this embodiment includes a pH sensitive carrier, a substance containing aluminum, and an aqueous solvent. Therefore, the adjuvant composition according to this embodiment is preferably in a form in which a pH-sensitive carrier and a substance containing aluminum are dispersed in an aqueous solvent.
- the adjuvant composition according to the present embodiment is such that the pH-sensitive carrier is deoxycholic acid, cholic acid, ursodeoxycholic acid, chenodeoxycholic acid, hyodeoxycholic acid, higher bile acid, glycodeoxychol.
- At least one pH-sensitive compound selected from the group consisting of acids, glycyrrhizic acid, glycyrrhetinic acid and salts thereof, phosphatidylcholine having only an acyl group having 10 to 12 carbon atoms, and having an acyl group having 12 to 18 carbon atoms
- at least one amphiphile is selected from the group consisting of ⁇ - tocopherol, include, expressing membrane disruption function promoting effect.
- FIG. 1 is a schematic diagram of an adjuvant composition according to one embodiment of the present invention and a vaccine composition containing the same.
- the adjuvant composition 4 includes an amphiphilic substance 1, a pH sensitive compound 2, and a substance 3 containing aluminum which is a substance having a stimulus for activating innate immunity.
- the substance 3 containing aluminum is associated with the pH-sensitive compound 2 in the hydrophobic part constituting the amphiphilic substance 1.
- the adjuvant composition 4 can also be referred to as an adjuvant complex.
- the substance 3 containing aluminum is present independently of the pH sensitive carrier comprising the amphiphilic substance 1 and the pH sensitive compound 2.
- the vaccine composition 6 includes an adjuvant composition 4 and an antigen 5.
- the antigen 5 may be included in the adjuvant composition 4 according to the above two forms, or may exist independently.
- the vaccine composition 6 in which the antigen 5 is included in the adjuvant complex 4 can also be referred to as a vaccine complex.
- the “adjuvant composition” means a substance containing a pH-sensitive carrier and a substance containing aluminum, and the form thereof is not particularly limited. That is, the “adjuvant composition” may be a mixture of a pH-sensitive carrier and a substance containing aluminum, or a substance containing or containing a substance containing aluminum in a pH-sensitive carrier (adjuvant complex). In the present specification, both are collectively referred to as an “adjuvant composition”.
- the “vaccine composition” means a composition containing an adjuvant composition and an antigen, and the form thereof is not particularly limited. That is, the “vaccine composition” may be a mixture of two or more selected from the group consisting of the components of the adjuvant composition and the antigen, or the adjuvant complex carries or includes the antigen. In the present specification, both are collectively referred to as a “vaccine composition”.
- the pH-sensitive carrier is sensitive to pH, and has a function of transporting intracellular antigens to the cytoplasmic substrate when the pH becomes acidic.
- the pH-sensitive carrier is not particularly limited, but deoxycholic acid, cholic acid, ursodeoxycholic acid, chenodeoxycholic acid, hyodeoxycholic acid, higher bile acids, glycodeoxycholic acid, glycyrrhizic acid, glycyrrhetinic acid and salts thereof
- At least one pH-sensitive compound selected from the group consisting of phosphatidylcholine having only an acyl group having 10 to 12 carbon atoms, polyoxyethylene sorbitan monofatty acid ester having an acyl group having 12 to 18 carbon atoms, and 16 to 16 carbon atoms From the group consisting of sorbitan fatty acid esters having only 18 acyl groups, glycerol monooleate, glycerol dilaurate, glycerol distearate, glycerol dioleate, polyoxyethylene castor oil and ⁇ -tocopherol Comprising at least one amphiphile
- pH sensitive carrier As the pH sensitive carrier according to the present embodiment, “pH sensitive carrier” described in International Publication No. 2013/180253 filed on May 24, 2013 can be used in the same manner.
- the pH-sensitive carrier is considered to be formed by association of a pH-sensitive compound and an amphiphilic substance at a physiological pH or higher. More specifically, the pH-sensitive carrier is considered to be formed by associating a pH-sensitive compound with a hydrophobic portion constituting an amphiphilic substance.
- the association format of the pH-sensitive carrier is speculation, and the pH-sensitive carrier is not limited to the association format.
- “Membrane destruction function promotion effect” means a function of causing dissolution in a dissolution test.
- the dissolution test in this specification refers to adding a liposome (dispersion) containing an aqueous solution containing a quenching substance and a fluorescent substance, and an evaluation sample dispersion to an aqueous solution adjusted to a predetermined pH, This is a test for measuring the fluorescence intensity of the aqueous solution after incubating the aqueous solution at 37 ° C. for 90 minutes or 30 minutes. By this method, the amount of the fluorescent substance eluted from the liposome can be measured, and the membrane breaking function of the pH sensitive carrier can be confirmed. In addition, about a dissolution test, it demonstrates in detail in the Example mentioned later.
- “expressing a membrane destruction function promoting effect” means (1) in the dissolution test, the dissolution rate at a predetermined pH lower than physiological pH is higher than the dissolution rate at physiological pH, and the increase width Is larger than the increase in the case of experimenting with the pH sensitive compound alone, and (2) in the dissolution test at a predetermined pH lower than the physiological pH, the pH sensitive compound and the amphiphile are complexed ( It means that the elution rate when the pH-sensitive carrier is formed is greater than the sum of the elution rate of the pH-sensitive compound alone and the elution rate of the amphiphile alone.
- a membrane destruction function promoting effect means that a pH-sensitive carrier (a complex of a pH-sensitive compound and an amphiphile) in an elution test between pH 7.4 and pH 5.0 or pH 4.5.
- Elution rate Lc satisfies the following relationship with the elution rate La of the pH-sensitive compound alone and the elution rate Lb of the amphiphilic substance alone. That is, said (1) is represented by following formula (1), and said (2) is represented by following formula (2).
- the elution rate at pH 7.4 is expressed as Lc 7.4 , La 7.4 , and Lb 7.4 , respectively, and the elution rate at pH 5.0 or 4.5 is expressed as Lc x , It is expressed as La x and Lb x .
- ⁇ only needs to exceed 0, but is preferably 2 or more, more preferably 2.5 or more, further preferably 5 or more, and 10 or more. It is particularly preferable that it is 30 or more.
- ⁇ ′ only needs to exceed 0, but is preferably 2 or more, more preferably 2.5 or more, and further preferably 3 or more. It is even more preferably 5 or more, particularly preferably 10 or more, and most preferably 15 or more.
- a pH sensitive carrier in which ⁇ and ⁇ ′ in the above formula (1) and the above formula (2) are each 2 or more (preferably 5 or more), and containing bile acid and lipid. preferable.
- ⁇ and ⁇ ′ in the above formula (1) and the above formula (2) are each 2 or more (preferably 5 or more), and glycyrrhizic acid or glycyrrhetinic acid, And a pH sensitive carrier comprising lipid.
- physiological pH in this specification means pH in normal tissue or normal body fluid.
- the physiological pH is usually 7.4, but varies slightly ( ⁇ 0.1) depending on normal tissues and normal body fluids.
- the “predetermined pH less than physiological pH” may be less than pH 7.4, preferably pH 3.0 or more, less than pH 7.4, more preferably pH 4.0 or more, less than pH 7.3,
- the pH is preferably 4.5 or more and less than 7.0.
- the mechanism by which the pH-sensitive carrier exerts the effect of promoting the membrane destruction function is not clear, but is presumed as follows.
- the present invention is not limited by the following estimation.
- the pH-sensitive carrier is considered to have an effect of promoting the membrane destruction function as a result of a change in the form of association between the pH-sensitive compound and the amphiphile when the surrounding environment is below physiological pH.
- a pH-sensitive carrier and a biological membrane for example, a cell membrane, a vesicle membrane, etc.
- the association form of the pH-sensitive carrier changes, After contact with the membrane, it is presumed that the membrane structure change of the biological membrane is also induced by the change. That is, the pH sensitive carrier induces a membrane structure change of the biological membrane.
- a pH-sensitive compound in the pH-sensitive carrier is destabilized in the structure of the carrier by changing the pH to weakly acidic, so that the pH-sensitive carrier is rearranged from the biological membrane present in the system.
- a pH-sensitive compound is considered to be a molecule that changes the state of hydrophobic association by protonation when the pH changes to weak acidity. That is, it can be said that a hydrophobic association containing a pH-sensitive compound can exhibit a membrane breaking function by responding to a weakly acidic environment.
- Membrane breakdown refers to such a change in the membrane structure, and it is not necessary that all membrane constituent components are separated or decomposed. When such “membrane destruction” occurs, components that can be contained inside the membrane of the biological membrane (eg, endosome) are eluted out of the biological membrane (eg, cytoplasmic substrate).
- the pH-sensitive carrier has a dissolution rate in a dissolution test of less than 20% at pH 7.4 and greater than 20% at pH 4.0.
- the dissolution rate in the dissolution test is more preferably less than 20% at pH 6.5 and more than 20% at pH 4.0.
- the elution rate at pH 7.4 or pH 6.5 is more preferably 15% or less, and further preferably 10% or less.
- the elution rate at pH 4.0 is more preferably 40% or more, and further preferably 50% or more.
- the dissolution rate in the dissolution test is preferably less than 20% at pH 7.4 and greater than 20% at pH 5.0.
- the adjuvant composition of this embodiment may use a pH-sensitive carrier having the effect of promoting the membrane destruction function as described above.
- the pH-sensitive carrier can express a membrane fusion function promoting effect as well as a membrane disrupting function promoting effect.
- membrane fusion function means a function of causing membrane fusion in a membrane fusion test.
- the membrane fusion test in the present specification is performed by adding a liposome (dispersion) in which two kinds of fluorescent substances are incorporated into a bilayer membrane and an evaluation sample dispersion to an aqueous solution adjusted to a predetermined pH, This is a test for measuring the fluorescence intensity of the aqueous solution after incubating the aqueous solution at 37 ° C. for 60 minutes. By this method, changes in energy resonance transfer of two types of fluorescent substances incorporated in the liposome can be measured, and the membrane fusion function of the pH-sensitive carrier can be confirmed.
- the membrane fusion test will be described in detail in the examples described later.
- expressing a membrane fusion function promoting effect means that in a membrane fusion test, the fusion rate at a predetermined pH lower than physiological pH is higher than the fusion rate at physiological pH, and the range of the increase is pH sensitive. It means satisfying that it is larger than the increase in the case of experimenting with the compound alone. More specifically, expression of a membrane fusion function promoting effect means that the fusion rate of a pH sensitive carrier (a complex of a pH sensitive compound and an amphiphile) in a membrane fusion test at pH 7.4 and pH 5.0.
- Rc (%) means the one satisfying the relationship of the fusion rate Ra (%) of the pH sensitive compound alone and the following formula (3). In the following formulae, the fusion rate at pH 7.4 is expressed as Rc 7.4 and Ra 7.4 , respectively, and the fusion rate at pH 5.0 is expressed as Rc x and Ra x , respectively.
- ⁇ R only needs to exceed 0, but is preferably 2 or more, more preferably 5 or more, and even more preferably 10 or more.
- the pH-sensitive carrier exhibits a membrane fusion function promoting effect at a weakly acidic pH (a predetermined pH lower than physiological pH). These mechanisms are not clear, but are considered to be the same mechanism as the above-described effect of promoting the film destruction function.
- the present invention is not limited by the estimation.
- the pH-sensitive carrier of the present invention changes the association form of the pH-sensitive compound and the amphiphile and rearranges it with the biological membrane present in the system. Therefore, it is estimated that membrane fusion occurs.
- a component eg, antigen
- an antigen is surrounded by an endosome, which is a type of biological membrane, and taken up by a cell (antigen-presenting cell or the like). Thereafter, the pH inside the endosome is lowered by the action of the proton pump. In addition, endosomes fuse with lysosomes containing hydrolases and the antigen is degraded (which can then be complexed with MHC class II molecules and presented to CD4 positive T cells). For this reason, most antigens are not delivered into the cytoplasmic matrix.
- an antigen for example, exogenous antigen
- an antigen can be delivered to the cytoplasmic substrate. More specifically, when an antigen is surrounded by an endosome together with a pH-sensitive carrier and taken up by a cell, it is similarly led to a reduced pH environment. As the pH decreases (acidification), the pH-sensitive compound destabilizes the pH-sensitive carrier, and membrane rearrangement occurs between the endosome and the pH-sensitive carrier. As a result, a membrane disrupting function (a membrane disrupting function that is expressed together with the membrane fusion function) by the pH-sensitive carrier occurs.
- antigens can be delivered from the endosome to the cytoplasmic substrate.
- the antigen can be transported to the cytoplasmic substrate as long as it is incorporated into the endosome together with the pH-sensitive carrier, so it is used in the form of a composition in which the antigen and the pH-sensitive carrier are mixed.
- the antigen may be used in a form supported or included in a pH sensitive carrier.
- the pH-sensitive compound is composed of deoxycholic acid, cholic acid, ursodeoxycholic acid, chenodeoxycholic acid, hyodeoxycholic acid, higher bile acid, glycodeoxycholic acid, glycyrrhizic acid, glycyrrhetinic acid and salts thereof as described above. It is preferably at least one selected from the group.
- the “salts” are not particularly limited, and examples thereof include alkali metal salts such as lithium, sodium and potassium; alkaline earth metal salts such as magnesium, calcium and barium; ammonium salts and the like. These pH sensitive compounds may be used alone or in combination of two or more.
- the pH-sensitive compound is a group consisting of deoxycholic acid, cholic acid, ursodeoxycholic acid, chenodeoxycholic acid, hyodeoxycholic acid, glycodeoxycholic acid, glycyrrhizic acid, and salts thereof. More preferably, it is at least one selected from.
- the pH-sensitive compound is a group consisting of deoxycholic acid, ursodeoxycholic acid, chenodeoxycholic acid, hyodeoxycholic acid, glycodeoxycholic acid, glycyrrhizic acid or a salt thereof. More preferably, it is at least one selected from the group consisting of deoxycholic acid, ursodeoxycholic acid, glycyrrhizic acid, or a salt thereof, and particularly preferably.
- Bile acids Deoxycholic acid, cholic acid, ursodeoxycholic acid, chenodeoxycholic acid, hyodeoxycholic acid, higher bile acids and glycodeoxycholic acids preferably used as pH-sensitive compounds are collectively referred to as bile acids.
- Bile acid has been known as a typical steroid derivative since the 1920s and is used in the field of bacteriology. Bile acids form a complex with cholesterol, lipids, and fat-soluble vitamins in the human body, and have a function of assisting in their absorption.
- the pH sensitive compound is preferably contained in a proportion of 10 mol or more, more preferably in a proportion of 10 to 640 mol, and more preferably in a proportion of 20 to 320 mol with respect to 100 mol of the amphiphilic substance. Is more preferable, and it is particularly preferable to be contained in a proportion of 20 to 160 mol.
- the content of the pH sensitive compound with respect to 100 mol of the amphiphilic substance is also referred to as “complexed amount of pH sensitive compound”.
- the amphiphilic substance includes phosphatidylcholine having only an acyl group having 10 to 12 carbon atoms, polyoxyethylene sorbitan monofatty acid ester having an acyl group having 12 to 18 carbon atoms, and an acyl group having 16 to 18 carbon atoms. It is preferably at least one selected from the group consisting of sorbitan fatty acid esters having only glycerol, glycerol monooleate, glycerol dilaurate, glycerol distearate, glycerol dioleate, polyoxyethylene castor oil, and ⁇ -tocopherol. These amphiphiles may be used alone or in combination of two or more.
- the “carbon number” in the amphiphilic substance means the carbon number of the fatty acid component (acyl group) constituting the hydrophobic part of the amphiphilic substance.
- the phosphatidylcholine having only an acyl group having 10 to 12 carbon atoms is preferably a diacylphosphatidylcholine having a saturated acyl group.
- a diacylphosphatidylcholine having a saturated acyl group for example, didecanoylphosphatidylcholine (DDPC; 1,2-didecanoyl-sn-glycero-3- Phosphatidylcholine) and dilauroylphosphatidylcholine (DLPC; 1,2-dilauroyl-sn-glycero-3-phosphatidylcholine).
- DDPC didecanoylphosphatidylcholine
- DLPC 1,2-dilauroylphosphatidylcholine
- phosphatidylcholine may be naturally derived or synthesized by a known method, or a commercially available product can be used.
- polyoxyethylene sorbitan monofatty acid ester having an acyl group having 12 to 18 carbon atoms examples include polyoxyethylene sorbitan monolaurate (polyoxyethylene sorbitan monolaurate), polyoxyethylene sorbitan myristate (polyoxyethylene sorbitan monoester). Myristate), polyoxyethylene sorbitan monopalmitate (polyoxyethylene sorbitan palmitate), polyoxyethylene sorbitan monostearate (polyoxyethylene sorbitan monostearate), polyoxyethylene sorbitan monooleate (polyoxy) Ethylene sorbitan monooleate).
- the polymerization degree of polyoxyethylene is not particularly limited, but the total polymerization degree of each polyoxyethylene chain added to sorbitan is preferably 10 to 200, more preferably 15 to 100, and 20 More preferably, it is ⁇ 50.
- the polyoxyethylene sorbitan monofatty acid ester a synthetic product or a commercially available product may be used. Examples of commercially available products of polyoxyethylene sorbitan monofatty acid ester include Tween 20 (polyoxyethylene sorbitan monolaurate), Tween 40 (polyoxyethylene sorbitan monopalmitate), Tween 60 (polyoxyethylene sorbitan monostearate), What is marketed as Tween 80 (polyoxyethylene sorbitan monooleate) can be preferably used. Among these, it is preferable to use polyoxyethylene sorbitan monofatty acid esters having 16 to 18 carbon atoms (Tween 20, Tween 40, Tween 60, Tween 80).
- sorbitan fatty acid esters having only an acyl group having 16 to 18 carbon atoms include sorbitan monopalmitate (sorbitan monopalmitate), sorbitan monostearate (sorbitan monostearate), sorbitan monooleate (sorbitan monooleate). Sorbitan monofatty acid esters such as sorbitan tripalmitate (sorbitan tripalmitate), sorbitan tristearate (sorbitan tristearate), sorbitan trioleate such as sorbitan trioleate (sorbitan trioleate), etc. Can be mentioned.
- sorbitan fatty acid ester a synthetic product or a commercially available product may be used.
- sorbitan fatty acid esters examples include SPAN40 (sorbitan palmitate), SPAN60 (sorbitan stearate), SPAN80 (sorbitan oleate), SPAN65 (sorbitan tristearate), and SPAN85 (sorbitan trioleate). What is marketed as ester is preferably used. Of these, SPAN80, SPAN65, and SPAN85 are preferably used.
- Glycerol monooleate (glyceryl monooleate), glycerol dilaurate (glyceryl dilaurate), glycerol distearate (glyceryl distearate), and glycerol dioleate (glyceryl dioleate) are ester-bonded to one or two molecules of fatty acid.
- the site to which the fatty acid binds is not particularly limited.
- a fatty acid may be ester-bonded to the C1 position or C2 position of glycerol.
- glycerol dilaurate, glycerol distearate, and glycerol dioleate which are diacylglycerols
- fatty acids may be ester-bonded at the C1 and C2 positions, or the C1 and C3 positions of glycerol.
- glycerol dilaurate is preferably ⁇ , ⁇ '-dilaurin in which the C1 and C3 positions are substituted.
- diacylglycerol substituted at the C1 position and the C2 position is preferable.
- synthetic products or commercially available products may be used.
- Polyoxyethylene castor oil is obtained by adding polyoxyethylene to castor oil.
- the degree of polymerization of polyoxyethylene is not particularly limited, but is preferably 3 to 200, more preferably 5 to 100, and still more preferably 10 to 50.
- As the polyoxyethylene castor oil a synthetic product or a commercially available product may be used.
- PEG (10) castor oil having a polyoxyethylene polymerization degree of 10 is preferably used.
- ⁇ -tocopherol a naturally-derived or synthesized method may be used, or a commercially available product may be used.
- phosphatidylcholine having only an acyl group having 10 to 12 carbon atoms, polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monooleate, sorbitan monooleate, polyoxyethylene castor oil and ⁇ -More preferably selected from the group consisting of tocopherols, dilauroyl phosphatidylcholine, didecanoyl phosphatidylcholine, polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monooleate, sorbitan monooleate, polyoxyethylene castor oil and More preferably, it is selected from the group consisting of ⁇ -tocopherol.
- the pH-sensitive carrier can express a membrane destruction function promoting effect at a desired pH by a combination of a pH-sensitive compound and an amphiphilic substance.
- the pH at which the effect of promoting the membrane destruction function of the pH-sensitive carrier begins to appear varies depending on the combination of the pH-sensitive compound and the amphiphilic substance. This is considered to originate from the fact that the pKa differs depending on the pH-sensitive compound, and further, the mode of association formation with the amphiphilic substance differs depending on the combination of the pH-sensitive compound and the amphiphilic substance. Therefore, by appropriately changing the combination of the pH-sensitive compound and the amphiphilic substance, it is possible to select a pH at which the function is expressed, and it is possible to set the delivery in detail.
- combinations of pH-sensitive compounds and amphiphiles include cholic acid and DLPC, deoxycholic acid and DDPC, deoxycholic acid and DLPC, deoxycholic acid and Tween 20, deoxycholic acid and Tween 40, deoxycholic Acid and Tween 60, Deoxycholic acid and Tween 80, Deoxycholic acid and SPAN40, Deoxycholic acid and SPAN60, Deoxycholic acid and SPAN80, Deoxycholic acid and SPAN65, Deoxycholic acid and SPAN85, Deoxycholic acid and SPAN85, Deoxycholic acid, Deoxycholic Acid and glycerol monooleate, deoxycholic acid and glycerol distearate, deoxycholic acid and di Glycerolate, deoxycholic acid and glycerol dilaurate ( ⁇ , ⁇ '-dilaurin), deoxycholic acid and polyoxyethylene castor oil, chenodeoxycholic acid and polyoxyethylene castor oil,
- cholic acid and DLPC deoxycholic acid and DDPC, deoxycholic acid and DLPC, deoxycholic acid and Tween 20, deoxycholic acid and Tween 40, deoxycholic acid and Tween 60, deoxycholic acid and Tween 80, deoxycholic acid and Tween 80, deoxycholic acid and SPAN 40 , Deoxycholic acid and SPAN 60, deoxycholic acid and SPAN 80, deoxycholic acid and SPAN 65, deoxycholic acid and SPAN 80, deoxycholic acid and SPAN 85, deoxycholic acid and ⁇ -tocopherol, deoxycholic acid and glycerol monooleate, deoxychol Acid and polyoxyethylene castor oil, chenodeoxycholic acid and DLPC, hyodeoxyco Luric acid and DLPC, Glyodeoxycholic acid and DLPC, Ursodeoxycholic acid and DDPC, Ursodeoxycholic acid and DLPC
- cholic acid and DLPC deoxycholic acid and DDPC, deoxycholic acid and DLPC, deoxycholic acid and Tween 20, deoxycholic acid and Tween 40, deoxycholic acid and Tween 60, deoxycholic acid and Tween 80, deoxycholic acid and Tween 80, deoxycholic acid and SPAN 40 , Deoxycholic acid and SPAN 60, deoxycholic acid and SPAN 80, deoxycholic acid and SPAN 65, deoxycholic acid and SPAN 80, deoxycholic acid and SPAN 85, deoxycholic acid and ⁇ -tocopherol, deoxycholic acid and glycerol monooleate, deoxychol Acid and polyoxyethylene castor oil, chenodeoxycholic acid and DLPC, hyodeoxy Lumpur acid and DLPC, glycodeoxycholic acid and DLPC, ursodeoxycholic acid and DDPC, ursodeoxycholic acid and DLPC,
- the adjuvant composition of the present invention comprises a pH-sensitive carrier composed of the above-mentioned amphiphile and a pH-sensitive compound, and a substance having a stimulus that activates innate immunity (hereinafter, “substance that activates innate immunity”). And a substance containing aluminum.
- a substance containing aluminum is one type of substance that activates innate immunity.
- a substance that activates innate immunity means a substance that is recognized by a structural pattern recognition receptor or that stimulates immunocompetent cells to bring the immunocompetent cells into an active state.
- alum is used as a general term for adjuvants containing aluminum. Therefore, “alum” also means “a substance containing aluminum”.
- the aluminum-containing substance used in the present invention is not particularly limited as long as cellular immunity can be induced by use in combination with a pH-sensitive carrier, but is preferably an aluminum salt, such as aluminum hydroxide ( Al (OH) 3 ), aluminum phosphate (AlPO 4 ), aluminum sulfate (Al 2 (SO 4 ) 3 ), potassium aluminum sulfate (alum, AlK (SO 4 ) 2 ⁇ 12H 2 O), aluminum chloride (AlCl 3) ) And the like.
- AlPO 4 aluminum phosphate
- Al 2 (SO 4 ) 3 aluminum sulfate
- potassium aluminum sulfate alum, AlK (SO 4 ) 2 ⁇ 12H 2 O
- AlCl 3 aluminum chloride
- the substance containing aluminum is aluminum hydroxide.
- Aluminum hydroxide and aluminum phosphate are insoluble in water. Therefore, when used in an adjuvant composition, it is preferably dispersed in a dispersion medium. By using such aluminum hydroxide and / or aluminum phosphate, It can be a gel type adjuvant.
- a commercially available aluminum compound can be used as the substance containing aluminum.
- aluminum hydroxide examples include “aluminum hydroxide” manufactured by Sigma-Aldrich, “AlumVax Hydroxide 2%” manufactured by OZ BIOSCIENCES, “Alhydrogel adjuvant 2%” manufactured by InvivoGen, and the like.
- Alhydrogel adjuvant 2% examples include “AlumVax Hydroxide 2%” and “Alhydrogel adjuvant 2%” are forms in which aluminum is dispersed in an aqueous solution at a concentration of about 10 mg / mL in terms of metal.
- aluminum phosphate examples include “aluminum phosphate” manufactured by Sigma-Aldrich, “AlumVax Phosphate 2%” manufactured by OZ BIOSCIENCES, “Adju-Phos” manufactured by Alpha Diagnostic International, Inc, and the like.
- Al phosphates examples include “aluminum phosphate” manufactured by Sigma-Aldrich, “AlumVax Phosphate 2%” manufactured by OZ BIOSCIENCES, “Adju-Phos” manufactured by Alpha Diagnostic International, Inc, and the like.
- Al phosphates examples include “aluminum phosphate” manufactured by Sigma-Aldrich, “AlumVax Phosphate 2%” manufactured by OZ BIOSCIENCES, “Adju-Phos” manufactured by Alpha Diagnostic International, Inc, and the like.
- Adju-Phos is a form in which aluminum is dispersed in an aqueous solution at a concentration of about 5 mg / mL in terms of metal.
- aluminum sulfate “aluminum sulfate” manufactured by Sigma-Aldrich can be used.
- potassium aluminum sulfate examples include “alum crystals” manufactured by InvivoGen.
- aluminum chloride “aluminum chloride” manufactured by Sigma-Aldrich can be used.
- the “aluminum-containing substance” in the form of a dispersion can be used as a dispersion.
- a “aluminum-containing substance” in the form of a dispersion is designated as a pH-sensitive carrier (dispersion of pH-sensitive carrier). (Solution)).
- the aluminum compound when a solid aluminum compound is used as aluminum hydroxide or aluminum phosphate, the aluminum compound is dispersed in a dispersion medium in advance before mixing with a pH sensitive carrier (dispersion of pH sensitive carrier). It is preferable to use in the form.
- aluminum sulfate, potassium aluminum sulfate or aluminum chloride When aluminum sulfate, potassium aluminum sulfate or aluminum chloride is used as a substance containing aluminum, it may be mixed with a pH sensitive carrier (dispersion of pH sensitive carrier) in a solid state, or these aluminum compounds may be mixed with an aqueous solvent in advance. It may be dissolved in and then mixed with a pH sensitive carrier (dispersion of pH sensitive carrier).
- the substance containing aluminum may be used alone or in combination of two or more.
- the content of the substance containing aluminum varies depending on the type of the substance containing aluminum, but the substance containing aluminum is 1 to 1000 ⁇ g in terms of aluminum metal with respect to 100 nmol of the amphiphilic substance. Preferably, it is contained in an amount of 1 to 500 ⁇ g, more preferably 1 to 100 ⁇ g. It is preferable that the content of the substance containing aluminum with respect to 100 nmol of the amphiphilic substance is 1 ⁇ g or more because an immune response can be suitably induced. On the other hand, the content of the substance containing aluminum with respect to 100 nmol of the amphiphilic substance is preferably 1000 ⁇ g or less because side reactions can be reduced. In particular, when the amphiphilic substance contained in 100 ⁇ L of the adjuvant composition is less than 10 nmol, the ratio of the substance containing aluminum per nmol of the amphiphilic substance is preferably 10 to 100 ⁇ g.
- the content (concentration) of the substance containing aluminum in the adjuvant composition is preferably 1 ⁇ g / 100 ⁇ L or more in terms of aluminum metal when the adjuvant composition is dispersed in an aqueous solvent. / 100 ⁇ L to 100 ⁇ g / 100 ⁇ L is more preferable, and 10 ⁇ g / 100 ⁇ L to 100 ⁇ g / 100 ⁇ L is even more preferable. It is preferable that the content of the substance containing aluminum is 1 ⁇ g / 100 ⁇ L or more because an immune response can be suitably induced. On the other hand, the content of the substance containing aluminum is preferably 100 ⁇ g / 100 ⁇ L or less because side reactions can be reduced.
- the adjuvant composition may contain an aqueous solvent (hereinafter sometimes referred to as “aqueous medium”).
- the pH-sensitive carrier and the substance containing aluminum can be a dispersion liquid (hereinafter also referred to as “aqueous solution”) dispersed in the aqueous solvent.
- the pH-sensitive carrier preferably forms a complex containing the pH-sensitive compound and the amphiphilic substance in an aqueous medium.
- the form of these complexes is not particularly limited, and the pH-sensitive compound and the amphiphilic substance may form a film, or a part or the whole of the pH-sensitive compound is associated with the structure formed by the amphiphilic substance. May be embedded.
- a pH-sensitive compound and an amphiphile are micelle-like particles (particles in which a pH-sensitive compound and an amphiphile are associated in a granular form by hydrophobic interaction, and typically have a monomolecular film structure. Is preferably formed.
- the micelle particles preferably have a particle size of 10 to 200 nm. More preferably, it is 100 nm.
- the micelle-like particles do not include those that form a lipid bilayer structure (for example, liposome).
- the particle diameter of the pH-sensitive carrier can be measured by a dynamic light scattering method (NanoZS90, manufactured by MALVERN Instruments).
- the adjuvant composition preferably forms a complex (adjuvant complex) containing a pH-sensitive carrier in which the complex is formed and a substance containing aluminum in an aqueous medium.
- a complex adjuvant complex
- the form of the complex is not particularly limited, but it is preferable that the pH-sensitive compound and the amphiphilic substance constituting the pH-sensitive carrier and the substance containing aluminum form micelle-like particles.
- the particle size of the micellar particles is preferably 10 to 200 nm, and more preferably 10 to 100 nm.
- aqueous solution containing the adjuvant composition at least one of a pH-sensitive compound, an amphiphilic substance, and a substance having an activity to stimulate innate immunity does not form an aggregate and exists in a free state. Good.
- the solvent of the aqueous solution containing the adjuvant composition of the present invention is preferably an aqueous solution containing a buffer, saccharides such as NaCl, glucose and sucrose.
- any known buffer can be used as appropriate as long as the pH of the adjuvant composition is maintained at a physiological pH or higher, and is not particularly limited.
- the buffer include phosphate buffer, citrate buffer, citrate-phosphate buffer, trishydroxymethylaminomethane-HCl buffer (Tris-HCl buffer), MES buffer (2-morpholinoethanesulfone).
- Acid buffer TES buffer (N-tris (hydroxymethyl) methyl-2-aminoethanesulfonic acid buffer), acetate buffer, MOPS buffer (3-morpholinopropanesulfonic acid buffer), MOPS-NaOH buffer Agent, HEPES buffer (4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid buffer), GOOD buffer such as HEPES-NaOH buffer, glycine-hydrochloric acid buffer, glycine-NaOH buffer, glycyl Amino acid buffers such as glycine-NaOH buffer and glycylglycine-KOH buffer; C acid buffer, borate -NaOH buffer, borate buffers such as boric acid buffer; or imidazole buffer are used.
- a phosphate buffer a citrate buffer, a citrate-phosphate buffer, a Tris-HCl buffer, a MES buffer, an acetate buffer, and a HEPES-NaOH buffer.
- concentration of the buffer is not particularly limited and is preferably 0.1 to 200 mM, more preferably 1 to 100 mM.
- buffer concentration refers to the concentration (mM) of the buffer contained in the aqueous solution.
- the concentration of saccharides such as NaCl, glucose and sucrose is not particularly limited and is preferably 0.1 to 200 mM, more preferably 1 to 150 mM.
- the concentration of the pH-sensitive carrier in the aqueous solution is not particularly limited, but the total molar concentration of the pH-sensitive compound and the amphiphile is preferably 7.3 ⁇ mol / L or more, and 8.0 ⁇ mol / L or more. Is more preferably 50 ⁇ mol / L or more, particularly preferably 100 ⁇ mol / L or more, and most preferably 1 mmol / L or more.
- the total molar concentration of the pH sensitive compound and the amphiphilic substance is preferably 500 mmol / L or less, more preferably 300 mmol / L or less, further preferably 280 mmol / L or less, It is particularly preferably 0.5 mmol / L or less, and most preferably 4.2 mmol / L or less.
- the total molar concentration of the pH-sensitive compound and the amphiphile is preferably 100 ⁇ mol / L to 300 mmol / L, and 1 mmol / L to 280 mmol / L. More preferably, it is L.
- the substance containing aluminum in the aqueous solution is preferably a substance containing aluminum so that the concentration of aluminum is preferably 1 ⁇ g / 100 ⁇ L to 100 ⁇ g / 100 ⁇ L, more preferably 10 ⁇ g / 100 ⁇ L to 100 ⁇ g / 100 ⁇ L. Is preferably used.
- the adjuvant composition may contain other components. Although it does not restrict
- the stabilizer is not particularly limited as long as it does not adversely affect the pH-sensitive carrier and the substance containing aluminum.
- a polyoxyethylene sorbitan tri-palmitate, a polyoxyethylene sorbitan trioleate, a polyoxyethylene sorbitan tri-fatty acid ester having 12 to 18 carbon atoms for example, Tween 65, Tween 85
- a polyoxyethylene laurate Polyoxyethylene myristic acid ester, polyoxyethylene palmitic acid ester, polyoxyethylene stearic acid ester C12-18 polyoxyethylene alkyl esters such as PEG20 stearyl ether, PEG23 lauryl ether
- polyoxyalkylene hydrogenated castor oil eg, PEG10 hydrogenated castor oil, PEG40 hydrogenated castor oil, PEG60 hydrogenated castor oil
- Saturated and unsaturated monofatty acids having 8 to 18 carbon atoms such as caprylin (glycerol octanoate), glycerol monocaprate, glycerol monolaurate, glycerol monomyristate, glycerol monopalmitate,
- C8-16 difatty acid glycerol C8-16 difatty acid glycerol; ⁇ -tocopherol acetate, castor oil, soybean oil, cholesterol, squalene, squalane, lactose, ascorbyl palmitate, benzyl benzoate, methyl paraoxybenzoate, ethyl paraoxybenzoate, paraoxybenzoate
- Known stabilizers such as propyl acid and butyl paraoxybenzoate can be used.
- the “carbon number” in the stabilizer means the carbon number of the fatty acid component (acyl group) constituting the hydrophobic part.
- the content of these other components is not particularly limited as long as it does not adversely affect the pH-sensitive carrier and the aluminum-containing substance, but it is preferably 150 mol or less and more than 0 mol with respect to 100 mol of the amphiphilic substance. And more preferably 66.4 mol or less.
- the adjuvant composition according to this embodiment can induce CTLs effectively when administered together with an antigen.
- the function of the pH-sensitive carrier for example, the membrane destruction function promoting effect (and the membrane fusion function promoting effect) is obtained. It can exhibit suitably.
- the function of the substance containing aluminum can be suitably exhibited.
- the pH-sensitive carrier contains a pH-sensitive compound and an amphiphilic substance, and has a membrane destruction function promoting effect (in some cases, a membrane destruction function promoting effect and a membrane fusion function promoting effect).
- the membrane destruction function promoting effect (and the membrane fusion function promoting effect) is, as described above, inducing the change in the association state of the pH sensitive carrier by the pH sensitive compound in an acidic environment, and in this case the amphipathic property It is based on rearrangement with a cell membrane such as an endosome by a substance.
- the pH sensitivity of the pH-sensitive compound does not fluctuate, so that the pH-sensitive compound can cause a change in the association state of the pH-sensitive carrier.
- an aluminum-containing substance is incorporated into an amphiphilic substance or exists independently of a pH-sensitive carrier, it does not affect the rearrangement of the cell membrane by the amphiphilic substance. . If it does so, even if the substance containing aluminum is used together with a pH sensitive support
- the material containing aluminum is, for example, only incorporated into the amphiphile of the pH sensitive carrier by hydrophobic interaction, or simply present independently of the pH sensitive carrier. Yes, its function is not impaired.
- the adjuvant composition according to the present embodiment when administered together with an antigen, can introduce the antigen into the cytoplasmic substrate by the function of the pH-sensitive carrier, and the substance containing aluminum acts on the cytoplasmic substrate.
- Cross presentation based on the introduced antigen can be preferably induced, and cellular immunity (CTL) can be effectively induced.
- CTL cellular immunity
- humoral immunity can also be suitably induced.
- exogenous antigens are usually decomposed into peptide fragments by endosomes in antigen-presenting cells, form complexes with MHC class II molecules, and presented to CD4-positive T cells.
- the pH-sensitive carrier contains the antigen and aluminum when rearranging the endosomal cell membrane. Substances can be introduced into the cytoplasmic matrix. However, in one embodiment, even if rearrangement occurs, some or all of the antigen and aluminum containing material may remain in the endosome. In one embodiment, when the antigen and the adjuvant composition are present independently, only a part of the endosome may take up only the antigen. Then, the antigen is decomposed into peptide fragments in the endosome, forms a complex with the MHC class II molecule, and is presented to CD4 positive T cells to induce humoral immunity.
- dendritic cells that are preferably inducing cross-presentation are in an immunologically activated state, the induction of humoral immunity is suitably expressed.
- dendritic cells that are preferably inducing cross-presentation actively produce cytokines that activate immunity (eg, IFN ⁇ ), and lead the surrounding environment to an environment suitable for immunity induction.
- humoral immunity can be induced together with or instead of the cross presentation.
- the vaccine composition includes an adjuvant composition and an antigen.
- adjuvant composition Since the above-mentioned adjuvant composition can be used, the description thereof is omitted here.
- the antigen is not particularly limited as long as it causes an immune response, but is preferably a peptide or protein.
- Examples of the peptide or protein include viral antigens, bacterial antigens, fungal antigens, protozoal or parasitic antigens, cancer antigens, allergy related antigens, disease related antigens, graft rejection related antigens, and the like.
- the viral antigen is not particularly limited, but human immunodeficiency virus (HIV) antigens such as gag, pol, and env gene product, Nef protein, reverse transcriptase, and other HIV components; Hepatitis virus antigens such as S, M, and L proteins, hepatitis B virus pre-S antigen, hepatitis C virus RNA, and viral components of hepatitis A, B, and C; hemagglutinin and neuraminidase, and others Influenza virus components such as influenza virus components; measles virus antigen; rubella virus antigen; rotavirus antigen; cytomegalovirus antigen; respiratory syncytial virus antigen; herpes simplex virus antigen; varicella zoster virus antigen; It includes the rabies virus antigen.
- HAV human immunodeficiency virus
- adenovirus retrovirus, picornavirus, herpes virus, rotavirus, hantavirus, coronavirus, togavirus, flavivirus, rhabdovirus, paramyxovirus, orthomyxovirus, bunyavirus, arenavirus, leo Peptides derived from viruses, papillomaviruses, parvoviruses, poxviruses, hepadnaviruses or spongy viruses.
- bacterial antigens such as pertussis toxin, fibrillary hemagglutinin, pertactin, FIM2, FIM3, adenylate cyclase, and other pertussis bacterial antigen components; diphtheria toxin or toxoid, etc.
- Diphtheria bacterial antigens such as diphtheria bacterial antigen components of tetanus toxin or toxoid, tetanus bacterial antigens such as other tetanus bacterial antigen components, streptococcal bacterial antigens; lipopolysaccharide, other gram-negative bacterial antigen components, etc.
- Gram-negative gonococcal bacterial antigens Mycolic acid, heat shock protein 65 (HSP65), 30 kDa major secreted protein, antigen 85A, other mycobacterial antigen components and other Mycobacterial bacterial antigens; Helicobacter pylori bacterial antigen component; Fungal bacterial antigens; Haemophilus influenzae bacterial antigens; anthrax bacterial antigens; rickettsial bacterial antigens, and the like.
- the fungal antigen is not particularly limited, and examples thereof include a Candida fungal antigen component; a histoplasma fungal antigen; a cryptococcal fungal antigen; a coccidioidofungal antigen;
- the protozoan or parasitic antigen is not particularly limited, and examples thereof include Plasmodium falciparum antigen; Toxoplasma antigen; Schistosomiasis antigen; Leishmania antigen; Trypanosoma cruzi antigen and the like.
- the cancer antigen is not particularly limited, and includes cancer antigens derived from the cell surface, cytoplasm, nucleus, organelle, etc. of the cells of the tumor tissue.
- cancers include leukemia, lymphoma, neural tumor, melanoma, breast cancer, lung cancer, head and neck cancer, gastric cancer, colon cancer, liver cancer, pancreatic cancer, cervical cancer, uterine cancer, ovarian cancer, vaginal cancer, testicular cancer, prostate cancer.
- cancer antigens include HER2 / neu (Human EGFR related 2), CEA (Carcinogenic Embryonic Antigen), MAGE (Melanoma-associated Antigen), and XAGE (Xantigen E).
- gp100 Melan / mart-1, Tyrosinase, PSA (Prostate Specific Antigen), PAP (Prostate Acid Phosphatase), p53, K-ras, N-ras, Bcr-Abl, MUC-1 (Mucin-1) Specific (Membrane Antigen), survi in, WT-1 (Wilms tumor suppressor gene 1), AFP (Alpha Fetoprotein), GPC (Glypican), EGFR (Epidermal Growth Factor Receptor), and the like.
- the allergy-related antigen is not particularly limited, but includes cedar pollen antigen, ragweed pollen antigen; pollen antigen such as ryegrass pollen antigen; animal-derived antigen such as house dust mite antigen and feline antigen; therapeutic agent such as histocompatibility antigen and penicillin. Is mentioned.
- the disease-related antigen (autoimmune disease, allergy, etc.) is not particularly limited, but diabetes, rheumatoid arthritis, myasthenia gravis, systemic lupus erythematosus, atopic dermatitis, psoriasis, Sjogren's syndrome, alopecia areata, Crohn's disease, Ulcerative colitis, conjunctivitis, keratoconjunctivitis, asthma, allergic asthma, proctitis, drug eruption, allergic encephalomyelitis, acute necrotizing hemorrhagic encephalopathy, aplastic anemia, erythroblastic anemia, idiopathic thrombocytopenia Disease, Wegener's granulomatosis, Stevens-Johnson syndrome, interstitial pulmonary fibrosis and the like.
- G9D65 glutamate decarboxylase 65
- natural DNA myelin basic protein
- myelin proteolipid protein acetylcholine receptor component
- thyroglobulin thyroid stimulation as examples of antigens involved in autoimmune diseases
- TSH thyroid stimulation
- the graft rejection-related antigen is not particularly limited, and examples include an antigenic component of a graft transplanted into a graft recipient such as a heart, lung, liver, pancreas, kidney, and nerve graft component.
- antigens may be used alone or in combination of two or more.
- the content of the antigen is preferably 3.2 to 400 ⁇ g, more preferably 16 ⁇ g to 80 ⁇ g, based on 100 nmol of the amphiphilic substance constituting the pH sensitive carrier.
- the incorporation rate of the antigen is not particularly limited, and the antigen and the adjuvant composition may exist independently, but is preferably 3% or more, more preferably 5 to 80%, and more preferably 10 to More preferably, it is 60%.
- the integration rate is 3% or more, for example, when the vaccine composition is endocytosed into cells, the possibility that the antigen is introduced into the same endosome as the adjuvant composition is high, and the effect of the invention is preferable. It is preferable because it can be obtained.
- the “antigen incorporation rate” mainly means the ratio of the antigen carried or included in the adjuvant composition, and the value measured by the method described in the examples is adopted.
- the vaccine composition may contain other pharmaceutical additives.
- the vaccine composition may be in the form of a solid preparation such as a tablet, powder or capsule, or in the form of a liquid preparation such as an injection preparation, but is preferably a liquid preparation.
- a liquid preparation it may be provided as a dry product that is regenerated with water or other suitable excipient at the time of use.
- the vaccine composition is a tablet or capsule
- an enteric coating by a usual method.
- enteric coating those normally used in this field can be used.
- Capsules can also contain either powder or liquid.
- excipients for example, sugars such as lactose, sucrose, starches such as corn starch, celluloses such as crystalline cellulose, gum arabic, aluminum metasilicate) Magnesium sulfate, calcium phosphate, etc.), lubricant (eg, magnesium stearate, talc, polyethylene glycol, etc.), binder (eg, mannitol, sugars such as sucrose, crystalline cellulose, polyvinylpyrrolidone, Hydroxypropylmethylcellulose), disintegrating agents (eg, starches such as potato starch, celluloses such as carboxymethylcellulose, cross-linked polyvinyl pyrrolidone, etc.), colorants, flavoring agents, and the like.
- excipients for example, sugars such as lactose, sucrose, starches such as corn starch, celluloses such as crystalline cellulose, gum arabic, aluminum metasilicate) Magnesium sulfate, calcium phosphate, etc.),
- the vaccine composition when the vaccine composition is a liquid preparation, a solvent (eg, physiological saline, sterilized water, buffer solution, etc.), a membrane stabilizer (eg, cholesterol), an isotonic agent (eg, sodium chloride, glucose, glycerin). Etc.), antioxidants (eg tocopherol, ascorbic acid, glutathione etc.), preservatives (eg chlorbutanol, parabens etc.) and the like.
- a solvent eg, physiological saline, sterilized water, buffer solution, etc.
- a membrane stabilizer eg, cholesterol
- an isotonic agent eg, sodium chloride, glucose, glycerin). Etc.
- antioxidants eg tocopherol, ascorbic acid, glutathione etc.
- preservatives eg chlorbutanol, parabens etc.
- the solvent used for manufacture of a vaccine composition may be sufficient as the said solvent.
- the vaccine composition can induce cellular immunity by efficiently cross-presenting the antigen.
- CTL can be induced.
- inducing cellular immunity refers to a control (ie, a mixture of an antigen and a substance containing aluminum) that has not been treated with a vaccine composition by the ELIspot method described herein. This means that a lot of spot formation can be obtained.
- the vaccine composition can induce humoral immunity.
- antibodies such as IgG
- humoral immunity means that the IgG antibody titer is higher than that of the control administered with the antigen.
- a method for treating or preventing a disease comprising administering an effective amount of the above vaccine composition to a subject in need of treatment or prevention.
- the administration method of the vaccine composition is not particularly limited, and is oral administration; intravenous injection, intraarterial injection, subcutaneous injection, intradermal injection, intramuscular injection, intrathecal injection, transdermal administration, transdermal absorption, etc.
- Parenteral administration and the like are used as antigens, administration by the parenteral route, particularly subcutaneous injection, intradermal injection, intramuscular injection, and intravenous injection.
- a vaccine composition in which an antigen is not carried in or contained in an adjuvant composition but is mixed independently is administered locally, specifically, in the form of subcutaneous administration, intradermal administration, or intramuscular administration. Is preferred.
- the above subject is preferably a mammal, particularly preferably a human.
- diseases include viral infections such as human immunodeficiency syndrome (HIV), hepatitis, influenza; bacterial infections such as pertussis, diphtheria, tetanus, tuberculosis, Helicobacter pylori, pneumococci, etc .; fungal infections such as Candida Protozoal or parasitic infections such as malaria; leukemia, lymphoma, neural tumor, melanoma, breast cancer, lung cancer, head and neck cancer, stomach cancer, colon cancer, liver cancer, pancreatic cancer, cervical cancer, uterine cancer, ovarian cancer, Vaginal cancer, testicular cancer, prostate cancer, penile cancer, bone tumor, blood vessel tumor, lip cancer, nasopharyngeal cancer, pharyngeal cancer, esophageal cancer, rectal cancer, gallbladder cancer, bile duct cancer, laryngeal cancer, lung cancer, bladder cancer, kidney cancer , Brain tumor, thyroid cancer, Hodgkin's disease, non-Ho
- a method for treating or preventing a disease is provided.
- the common general technical knowledge at the time of filing can be referred to as appropriate.
- the vaccine composition can also transport the antigen to cells by culturing. That is, according to one aspect of the present invention, a culture method for transporting an antigen to cells is provided.
- the culture method includes a step of culturing the cells in a medium containing the vaccine composition.
- the medium is not particularly limited, and a known medium can be used. Specifically, MEM, DMEM, RPMI, etc. are mentioned.
- the amount of the vaccine composition added to the medium is not particularly limited, but the molar concentration of the amphiphile is preferably 0.66 ⁇ mol / L to 1.0 mmol / L, preferably 6.6 ⁇ mol / L to 0. It is more preferably 0.888 mmol / L, and even more preferably 7.2 ⁇ mol / L to 0.56 mmol / L.
- the pH of the medium is preferably 7.0 or more, more preferably 7.2 to 7.8. It is preferable that the pH of the medium is 7.0 or more because destabilization of the pH sensitive compound constituting the pH sensitive carrier in the medium can be prevented.
- the cells are not particularly limited, and examples include cells collected from subjects and established cultured cells.
- cells collected from the subject or established cultured cells include dendritic cells, NK (Natural Killer) cells, T cells, B sphere cells, lymphocyte cells, and the like.
- cells collected from the subject are preferably used, and dendritic cells, NK cells, T cells, lymphocyte cells, etc. collected from the subject are more preferably used, and dendritic cells are used. More preferably.
- the cells are collected from the subject by blood collection, biopsy, or the like. That is, in one embodiment, the culture method may include a step of collecting cells from a subject.
- the cultured cells may be administered to the subject.
- a subject's disease can be treated or prevented. That is, in one embodiment of the present invention, a method for treating or preventing a disease is provided.
- the treatment or prevention method comprises the steps of collecting cells from a subject, culturing the collected cells in a medium containing a vaccine composition, and administering the cultured cells to the subject. And a step of performing.
- the disease is as described above.
- the adjuvant composition according to the present invention is not particularly limited, and can be produced by various methods.
- an adjuvant composition in which a pH-sensitive carrier and an aluminum-containing substance are independently present can be produced by mixing a pH-sensitive carrier and an aluminum-containing substance.
- an adjuvant composition in which a substance containing aluminum is supported or included in a pH-sensitive carrier can be produced by associating a pH-sensitive carrier with a substance containing aluminum.
- the method for producing an adjuvant composition includes deoxycholic acid, cholic acid, ursodeoxycholic acid, chenodeoxycholic acid, hyodeoxycholic acid, higher bile acids, glycodeoxycholic acid, glycyrrhizic acid, glycyrrhetinic acid and salts thereof
- At least one pH-sensitive compound selected from the group consisting of: phosphatidylcholine having only an acyl group having 10 to 12 carbon atoms, polyoxyethylene sorbitan monofatty acid ester having an acyl group having 12 to 18 carbon atoms, carbon number 16 From the group consisting of sorbitan fatty acid esters having only ⁇ 18 acyl groups, glycerol monooleate, glycerol dilaurate, glycerol distearate, glycerol dioleate, polyoxyethylene castor oil and ⁇ -tocopherol Comprising at least one amphiphile is-
- the pH-sensitive compound, the amphiphilic substance, and the aluminum-containing substance may be contacted in an aqueous solution. Therefore, the adjuvant composition according to the present embodiment can be produced by bringing a pH-sensitive compound, an amphiphilic substance, and a substance containing aluminum into contact with each other in an aqueous solution.
- the method of bringing the pH-sensitive compound, the amphiphilic substance, and the aluminum-containing substance into contact with each other in an aqueous solution is not particularly limited as long as they form an aggregate.
- (1) ⁇ a> prepare an aqueous solution containing a pH-sensitive compound, an aqueous solution containing an amphiphilic substance, and an aqueous solution containing an aluminum-containing substance, and mix these aqueous solutions; A method in which the solution is vigorously stirred and dispersed using an emulsifier or the like to obtain an adjuvant composition;
- ⁇ C> A pH-sensitive compound
- the dispersion is mixed with an aluminum-containing substance or an aqueous solution containing an aluminum-containing substance to obtain an adjuvant composition; (2) by a Bangham method known as a liposome production method
- the method of preparation etc. are mentioned.
- a concrete method of the said bangham method it can carry out with the following method, for example. That is, the constituents of the pH-sensitive carrier are dissolved in an organic solvent (for example, methanol, chloroform) in a glass container, and the organic solvent is removed by a rotary evaporator or the like to form a thin film on the wall of the glass container.
- an organic solvent for example, methanol, chloroform
- the aqueous solution is added to the glass container on which the thin film is formed, and the thin film is swollen at 5 to 35 ° C., and then the glass container is shaken at 5 to 35 ° C.
- the thin film can be sufficiently dispersed in the aqueous solution by vigorously stirring using an emulsifier, a vortex mixer, and ultrasonic waves.
- an aqueous solution containing a pH sensitive carrier (dispersion of pH sensitive carrier) can be obtained.
- An adjuvant composition is obtained by mixing an aqueous solution containing the pH-sensitive carrier (dispersion of pH-sensitive carrier) and an aqueous solution containing a substance containing aluminum.
- an adjuvant composition can be obtained by dispersing the thin film.
- liposome production methods such as “Liposome” (Shinochi Nojima, Junzo Sunamoto, Junzo Inoue, Nanedou) and “Liposome in Life Science” (Terada). Hiro, Tetsuro Yoshimura, Springer Fairlake Tokyo).
- an emulsifier, a vortex mixer, an ultrasonic wave, or the like may be used to disperse strongly when preparing a dispersion.
- a pH-sensitive compound and a substance containing aluminum may be mixed in an aqueous solution containing an amphiphilic substance.
- the solvent of the aqueous solution mentioned above can be used as a solvent of an aqueous solution.
- the temperature at which each aqueous solution is prepared and the temperature at which the aqueous solution is mixed are not particularly limited, but are preferably 5 to 35 ° C., and 15 to 25 ° C. at normal temperature. Is more preferable.
- the addition method in particular of other components, such as a stabilizer which can be contained in the adjuvant composition containing an aqueous solvent as a component is not restrict
- it may be added to an aqueous solution containing a pH-sensitive compound, an aqueous solution containing an amphiphilic substance, and / or an aqueous solution containing a substance containing aluminum, or when preparing a thin film by the Bangham method,
- An aqueous solution containing the adjuvant composition may be obtained by dissolving together with the components of the adjuvant composition and using a thin film containing these components.
- aqueous solution containing the pH-sensitive compound, the aqueous solution containing the amphiphilic substance, and the aqueous solution containing the aluminum-containing substance are the same as those used in the “method for producing a vaccine composition” described later, or Those prepared with reference may be used.
- a method for producing a vaccine composition according to one embodiment comprises deoxycholic acid, cholic acid, ursodeoxycholic acid, chenodeoxycholic acid, hyodeoxycholic acid, higher bile acids, glycodeoxycholic acid, glycyrrhizic acid, glycyrrhetinic acid and their At least one pH-sensitive compound selected from the group consisting of salts, phosphatidylcholine having only an acyl group having 10 to 12 carbon atoms, polyoxyethylene sorbitan monofatty acid ester having an acyl group having 12 to 18 carbon atoms, carbon number Selected from the group consisting of sorbitan fatty acid esters having only 16-18 acyl groups, glycerol monooleate, glycerol dilaurate, glycerol distearate,
- the antigen may be mixed with an aqueous solution containing the aggregate.
- a vaccine composition can be obtained by mixing the adjuvant composition obtained by the above method (1) or (2) with an antigen.
- (V-1) ⁇ a> an aqueous solution containing a pH sensitive compound, an aqueous solution containing an amphiphilic substance, an aqueous solution containing an aluminum containing substance, an aqueous solution containing an antigen, Are prepared separately, these aqueous solutions are mixed, the solution is vigorously stirred and dispersed using an emulsifier or the like to obtain a vaccine composition;
- a solution containing an aluminum-containing substance and an antigen may be used as the aqueous solution to be added to the thin film formed of the constituents of the pH-sensitive carrier.
- an aqueous solution to be added to the thin film an aqueous solution containing an antigen may be used, and then an aqueous solution containing a substance containing aluminum may be mixed.
- the temperature at which the aqueous solution containing the antigen is mixed with the dispersion of the adjuvant composition or the pH-sensitive carrier is not particularly limited, but is preferably 5 to 35 ° C., preferably 15 to 25 ° C. at normal temperature.
- aqueous solution containing a pH-sensitive compound an aqueous solution containing an amphiphilic substance, an aqueous solution containing an aluminum-containing substance, an aqueous solution containing an antigen, and an aqueous solution containing an antigen and an aluminum-containing substance are described below. Those prepared as described above can be used.
- the solution containing the pH sensitive compound contains a pH sensitive compound and a solvent. Moreover, the additive may be included as needed.
- an aqueous solution containing a saccharide such as a buffer, NaCl, glucose, sucrose, or sterilized water can be used.
- a saccharide such as a buffer, NaCl, glucose, sucrose, or sterilized water
- physiological saline, sterilized water, and buffer are preferably used from the viewpoint of suitably administering the vaccine composition to a living body.
- the molar concentration of the pH-sensitive compound is preferably 5 ⁇ mol / L or more, more preferably 10 ⁇ mol / L or more, and further preferably 50 ⁇ mol / L or more, It is particularly preferably 100 ⁇ mol / L or more, and most preferably 1 mmol / L or more. Further, the molar concentration of the pH sensitive compound in the aqueous solution is preferably 500 mmol / L or less, more preferably 300 mmol / L or less, further preferably 250 mmol / L or less, 200 mmol / L or less. Is particularly preferred.
- the molar concentration of the pH-sensitive compound is preferably 100 ⁇ mol / L to 300 mmol / L, and more preferably 1 mmol / L to 200 mmol / L.
- the solution containing the amphiphile contains an amphiphile and a solvent. Moreover, the additive may be included as needed.
- amphiphilic substance and the solvent those described above can be used, and thus the description thereof is omitted here.
- the molar concentration of the amphiphile is preferably 5 ⁇ mol / L or more, more preferably 10 ⁇ mol / L or more, and more preferably 50 ⁇ mol / L or more. It is preferably 100 ⁇ mol / L or more, and most preferably 500 ⁇ mol / L or more. Further, the molar concentration of the amphiphile in the aqueous solution is preferably 500 mmol / L or less, more preferably 300 mmol / L or less, further preferably 250 mmol / L or less, and 200 mmol / L. The following is particularly preferable, and it is most preferable that it is 150 mmol / L or less.
- the molar concentration of the amphiphile is preferably 50 ⁇ mol / L to 200 mmol / L, and more preferably 500 ⁇ mol / L to 150 mmol / L.
- the solution containing the substance containing aluminum contains a substance containing aluminum and a solvent. Moreover, the additive may be included as needed.
- the concentration of aluminum in the aqueous solution containing the substance containing aluminum is preferably 1 ⁇ g / 100 ⁇ L to 100 ⁇ g / 100 ⁇ L, more preferably 10 ⁇ g / 100 ⁇ L to 100 ⁇ g / 100 ⁇ L in terms of aluminum metal.
- the solution containing the antigen contains an antigen and a solvent.
- antigen and the solvent those described above can be used, and therefore the description thereof is omitted here.
- the mixing method of the aqueous solution containing the above-mentioned pH sensitive compound, the aqueous solution containing the amphiphilic substance, the aqueous solution containing the aluminum-containing substance, and the aqueous solution containing the antigen is not particularly limited.
- the stirring can be performed using, for example, an emulsifier, a vortex mixer, an ultrasonic wave, or the like.
- the aqueous solution containing the pH-sensitive compound, the aqueous solution containing the amphiphile, the aqueous solution containing the aluminum-containing material, and the aqueous solution containing the antigen are not separate solutions, but two types. It is good also as a liquid mixture which combined the above component.
- an aqueous solution containing a pH-sensitive compound and a substance containing aluminum may be prepared, and this may be mixed with an aqueous solution containing an amphiphilic substance or an aqueous solution containing an antigen.
- CpG-DNA CpG-ODN: manufactured by InvivoGen, ODN-2395
- Tocopherol acetate DL- ⁇ -tocopherol acetate: manufactured by Nacalai Tesque
- Aluminum hydroxide InvivoGen, Alhydrogel 2%)
- Aluminum phosphate manufactured by Alpha Diagnostic International, Adjuphos
- -Potassium aluminum sulfate InvivoGen, alum crystals
- Solvents, water for injection: (Otsuka Pharmaceutical Co., Ltd.) ⁇ MES-Na (Merck) ⁇ Sodium chloride (manufactured by Kanto Chemical)
- PBS Tables Phosphate buffered saline: manufactured by Takara Bio Inc.
- Methanol Nacalai Tesque
- Ethanol Karlo Chemical Co., Ltd.
- Chloroform Chloroform (Wako Pure Chemical Industries) Sodium hydroxide aqueous solution (0.1 mol
- Ultrasonic irradiation device USC-J Spectrophotometer: FP-6500
- UV-vis spectrophotometer UV-3600 CO 2
- incubator MCO20AIC ⁇ Cell culture> The cells were cultured using an incubator (MCO20AIC) set at 5% CO 2 and 37 ° C.
- MES Buffer MES: 25 mM and NaCl: 125 mM were prepared.
- MES Buffer has a pH of 7.4 unless otherwise specified.
- PBS PBS
- the PBS was prepared by dissolving 10 tablets of PBS Tables (manufactured by Takara Bio Inc.) in 1000 mL of distilled water. The pH is 7.35 to 7.65. Alternatively, purchased D-PBS was used as PBS.
- RPMI medium Penicillin (100 units / mL) and streptomycin (100 mg / mL) were added as antibiotics. Further, FBS was additionally added as necessary to obtain a RPMI medium containing 10% serum.
- -Primary solution of tocopherol 10 mg of tocopherol was weighed and dissolved in 1.0 mL of ethanol. Furthermore, it diluted 10 times with PBS and the primary solution of tocopherol was prepared.
- -Primary solution of tocopherol acetate 10 mg of tocopherol acetate was weighed and dissolved in 1.0 mL of ethanol. Further, the solution was diluted 10 times with PBS to prepare a primary solution of tocopherol acetate.
- alum aluminum hydroxide, aluminum phosphate, and potassium aluminum sulfate (alum) were used.
- the alum used is aluminum hydroxide
- the stock solution of the purchased reagent aluminum concentration (aluminum metal equivalent): about 10 mg / mL
- the adjuvant composition Used for the preparation of
- the stock solution of the purchased reagent was diluted with PBS to obtain a primary solution of alum, which was used for the preparation of an adjuvant composition.
- the stock solution of the purchased reagent was diluted 10-fold with PBS and used for the preparation of an adjuvant composition.
- the final concentration is 1 ⁇ g / 100 ⁇ L, it is diluted 100 times with PBS, and when the final concentration is 0.1 ⁇ g / 100 ⁇ L, a solution diluted 1000 times with PBS is used as the primary solution for alum. Used in the preparation of the adjuvant composition.
- the alum used is aluminum phosphate, as with aluminum hydroxide, the stock solution of the purchased reagent and the diluted stock solution of the purchased reagent in PBS are used as the primary solution for alum and used for the preparation of the adjuvant composition. It was.
- a predetermined amount of a pH-sensitive compound was weighed and dissolved in MES Buffer or PBS to prepare a solution of the pH-sensitive compound.
- a predetermined amount of amphiphilic substance was weighed, added to the previously prepared pH-sensitive compound, and mixed to prepare a pH-sensitive carrier dispersion (solution).
- the operation was performed at room temperature. Specifically, in the case of a pH sensitive carrier consisting of 1600 nmol deoxycholic acid with respect to 1000 nmol DLPC, 13.8 mg sodium deoxycholate monohydrate is weighed and dissolved in 10 mL MES Buffer or PBS. It was.
- the ratio of the amphiphile to the pH-sensitive compound was adjusted to a desired ratio. Further, when a plurality of amphiphiles were used, the total amount of the amphiphiles was adjusted to a desired number of moles (1000 nmol). Moreover, the usage-amount of the pH sensitive compound in description of an Example or a figure is a usage-amount with respect to 100 nmol amphiphile.
- a primary solution of a substance that stimulates innate immunity (hereinafter also referred to as a candidate substance) was added to and mixed with the prepared dispersion (solution) of a pH-sensitive carrier. Additional MES to adjust concentration An adjuvant composition was prepared by adding and mixing Buffer or PBS.
- a vaccine composition was prepared by adding and mixing PBS in which a predetermined amount of OVA was dissolved to the obtained adjuvant composition.
- a pH-sensitive carrier, an adjuvant composition, and a vaccine composition were prepared so as to have an amphiphilic substance concentration of 100 nmol / 100 ⁇ L.
- a dispersion (solution) of a pH sensitive carrier was diluted and used.
- the vaccine composition was prepared so as to have an amphiphile concentration of 100 nmol / 100 ⁇ L to 0.1 nmol / 100 ⁇ L.
- CpG-DNA CpG-ODN
- 200 ⁇ g of CpG-ODN was dissolved in 200 ⁇ L of water for injection to make a primary solution of a candidate substance, which was used for the preparation of an adjuvant composition.
- comparative sample As a comparative sample, an antigen alone or a mixture of an antigen and a candidate substance (also indicated as a candidate substance alone) was prepared. In the dissolution test, a dispersion of amphiphile alone and a dispersion of pH-sensitive carrier alone were also prepared.
- ⁇ Measurement method> (Dissolution test: Leakage (dissolution rate) measurement) Leakage (elution rate) Kono et al. Bioconjugate Chem. According to the method described in 2008 19 1040-1048, evaluation was performed using EYPC liposomes encapsulating Pyranine as a fluorescent substance and DPX as a quencher.
- the elution rate was calculated with 0% for the EYPC liposome dispersion alone and 100% for 30 ⁇ L of 10-fold diluted Triton-X100. Specifically, the dissolution rate was calculated according to the following formula. In the following formula, the measured fluorescence intensity is L, the fluorescence intensity of only the EYPC liposome dispersion containing the fluorescent substance is L 0 , and the fluorescence intensity when Triton-X100 is added is L 100 .
- EYPC EYPC 1000 nmol
- MES Buffer 1.0 mL
- USC-J ultrasonic irradiation apparatus
- the fusion rate was determined by setting the fluorescence intensity ratio when the double fluorescently labeled EYPC liposome dispersion obtained above and the amphiphile were incubated to 0%, and the double fluorescently labeled EYPC liposome dispersion and the evaluation sample
- the dispersion was treated with methanol and calculated as 100%.
- both the double fluorescence-labeled EYPC liposome dispersion and the evaluation sample dispersion were dissolved in methanol, and then formed into a thin film using a rotary evaporator. A 3.0 mL MES buffer and an ultrasonic irradiation device were used. And dispersed.
- the fusion rate was calculated according to the following formula.
- the fluorescence intensity ratio obtained by measurement is R
- the fluorescence intensity ratio when the double fluorescently labeled EYPC liposome dispersion and the amphiphile are incubated is R 0
- double fluorescence labeled fluorescence intensity ratio of EYPC liposome dispersion and evaluation samples dispersion obtained by methanol treatment was represented as R 100.
- intradermal injection was performed at 20 ⁇ L / head in one place on the back using the same administration solution as that for subcutaneous administration.
- the administration was performed once and the assay was performed 7 days after the administration.
- humoral immunity administration was carried out twice, and the second administration was performed 14 days after the first administration.
- the assay was performed 14 days after the second dose.
- mice were euthanized and the spleen was removed. After adding 3.0 mL of 10% serum-containing RPMI medium, the spleen was treated with a BD Falcon cell strainer to obtain a cell suspension. After hemolysis operation using RBC lysis buffer, the cells were washed with RPMI medium containing 10% serum. The cells were dispersed with RPMI medium containing 10% serum, and then the number of cells was counted to obtain a spleen cell dispersion.
- the ELIspot method was performed using a Mouse IFN ⁇ ELISPOT Set. The day before seeding the cells, the detection antibody attached to the kit was adsorbed to a 96-well ELIspot plate to prepare a plate. The prepared plate was washed with 10% serum-containing RPMI medium, 200 ⁇ L of 10% serum-containing RPMI medium was added, and the plate was allowed to stand at 37 ° C. for 2 hours for blocking. When antigen stimulation is added after washing the plate with 10% serum-containing RPMI medium, 100 ⁇ L of 10% serum-containing RPMI medium containing 40 ⁇ g / mL of OVA peptide is added to the plate, and antigen restimulation is added.
- the plate was colored according to the protocol described in Mouse IFN ⁇ ELISPOT Set and AEC Substrate Set.
- the OVA protein was dissolved in a coating buffer and added to a 96-well plate so that the concentration was 0.1 ⁇ g / well (100 ⁇ L). After leaving still at 37 degreeC for 2 hours, it replaced with 300 microliters Block buffer, and left still at 4 degreeC overnight. After washing the plate, 100 ⁇ L of serum diluted to a predetermined magnification was added to each well and allowed to stand at 37 ° C. for 2 hours. After the plate was washed, 100 ⁇ L of a secondary antibody solution diluted 1000 times with Block buffer was added to each well, and the plate was allowed to stand at 37 ° C. for 2 hours. After the plate was washed, color was developed using a peroxidase coloring kit to determine the antibody titer.
- the pH sensitive carrier used was a complex of 100 nmol DLPC and 160 nmol deoxycholic acid per animal.
- Candidate substances were all 10 ⁇ g per animal, and 80 ⁇ g of OVA protein was used for each antigen.
- the administration liquid was prepared by adding a pH-sensitive carrier dispersion (solution), a candidate substance, and an antigen in this order to PBS for preparing a dosage and mixing them.
- the administration solution was prepared so that the pH-sensitive carrier dispersion (solution), candidate substance, and antigen had a predetermined concentration in 100 ⁇ L.
- the dose was 100 ⁇ L per animal, and the route of administration was subcutaneous. Induction of cellular immunity was evaluated according to the ELIspot method described above.
- the induction of cellular immunity (CTL) by the ELIspot method was evaluated by the following criteria by comparison with a control (mixture of a substance containing an antigen and aluminum) visually.
- ⁇ Cellular immunity is clearly induced compared to the control.
- ⁇ Cellular immunity is slightly induced compared to the control.
- ⁇ Cellular immunity is equal to or less than that of the control. .
- tocopherol and pH-sensitive carrier are similar to the number of spots formed by alum alone (antigen + alum in FIG. 2 (D)), and cannot induce cellular immunity. (FIGS. 2E and 2F).
- the combined use of alum and a pH-sensitive carrier formed a very large number of spots compared to the formation of alum alone (FIG. 2 (G)). It has been shown that the use of alum and a pH-sensitive carrier leads to induction of cellular immunity. From these results, it was shown that alum is a substance that stimulates (activates) innate immunity suitable for use in combination with a pH-sensitive carrier.
- CpG-ODN is a synthetic oligonucleotide having a specific base sequence and is a reagent that has been reported to induce cellular immunity. Using this reagent as a positive control, the high activity of inducing cellular immunity by the combined use of alum and a pH-sensitive carrier was evaluated. CpG-ODN was used at 10 ⁇ g per animal, and all other experimental conditions were the same as (1). Evaluation was performed on the same plate as the ELIspot of (1).
- the number of spots formed by the combined use of alum and a pH-sensitive carrier was larger than that obtained by CpG-ODN (FIGS. 3B and 3C). Since the activity was higher than that of CpG-ODN which is a generally known reagent, it was revealed that the combined use of alum and a pH-sensitive carrier enables high induction of cellular immunity.
- the induced immunity is antigen-specific. Therefore, the antigen specificity was evaluated for cellular immunity induced by the combined use of alum and a pH-sensitive carrier.
- the evaluation was performed according to the above-described ELIspot method in which no re-stimulation was applied. Specifically, a dispersion of spleen cells collected from the immunized animal was seeded on an ELIspot plate, and spot formation by IFN- ⁇ producing cells was performed without adding SIINFEKL peptide. As a result, no spot formation was observed, and the formation of the spot obtained by the combined use of alum and the pH-sensitive carrier in FIG. 3 (B) completely disappeared (FIG. 3 (D)).
- the cellular immunity induced by the combined use of alum and a pH sensitive carrier has indeed been shown to be antigen specific. The induced cells reacted with SIINFEKL class I peptide, suggesting that they were CTL.
- alum aluminum hydroxide
- Alum used aluminum hydroxide and the pH-sensitive carrier used a complex of DLPC and deoxycholic acid (100 nmol DLPC and 160 nmol deoxycholic acid per animal).
- Alum was 100-0.1 ⁇ g per mouse, and 80 ⁇ g of OVA protein was used per antigen.
- the administration liquid was prepared by adding and mixing PBS, alum, and antigen in order of the dosage to a dispersion (solution) of a pH sensitive carrier. The dose was 100 ⁇ L per animal, and the route of administration was subcutaneous. Induction of cellular immunity was evaluated according to the ELIspot method described above.
- Alum alone refers to a mixture of an antigen and alum.
- the vaccine composition (100 ⁇ g / 100 ⁇ L to 1 ⁇ g / 100 ⁇ L as the alum concentration in the solution) that is 100 to 1 ⁇ g of alum (in the figure, antigen + alum + pH sensitive carrier) has the number of spots formed, (In the figure, it was more than that due to antigen + alum) (FIGS. 4B, 4C, 4D, and 4E).
- the amount of alum used was 0.1 ⁇ g, the number of spots formed was equivalent to that of alum alone (FIGS. 4B and 4F).
- the administration solution prepared with DLPC constituting the pH-sensitive carrier at a concentration of 1 to 1000 nmol / 100 ⁇ L and deoxycholic acid at a concentration of 1.6 to 160 nmol / 1000 ⁇ L induces cellular immunity. It was. That is, it was suggested that the vaccine composition induces cellular immunity when the concentration of the amphiphile constituting the pH-sensitive carrier is 1-1000 nmol / 100 ⁇ L.
- Induction of humoral immunity was evaluated by IgG antibody titer.
- a dose per dose 10 ⁇ g of aluminum hydroxide was used for alum, and a complex consisting of 100 nmol of DLPC and 160 nmol of deoxycholic acid was used as the pH sensitive carrier.
- the antigen was 80 ⁇ g of OVA protein.
- the administration liquid was prepared by adding and mixing PBS, alum, and antigen in order of the dosage to a dispersion (solution) of a pH sensitive carrier.
- the dose was 100 ⁇ L per animal, and the route of administration was subcutaneous.
- administration was performed twice.
- the antibody titer was evaluated according to the measurement of the antibody titer described above.
- alum alone showed the highest IgG antibody titer
- the combined use of alum and a pH-sensitive carrier showed the next highest antibody titer (FIG. 6, twice administration).
- the combined use of alum and a pH-sensitive carrier showed a high IgG antibody titer compared to the PBS and antigen-only groups (FIG. 6, twice administration). From this result, it was shown that a vaccine composition using alum and a pH-sensitive carrier can induce humoral immunity.
- the adjuvant composition according to the present invention can be used as an excellent adjuvant.
- alum is used as a general term for aluminum-containing adjuvants.
- examples of alum include aluminum hydroxide, aluminum phosphate, potassium aluminum sulfate (alum), and aluminum chloride.
- cell immunity can be obtained by using in combination with a pH-sensitive carrier. We investigated what could be induced.
- alum used was aluminum phosphate and potassium aluminum sulfate (alum).
- the pH sensitive carrier used was a complex of DLPC and deoxycholic acid (100 nmol DLPC and 160 nmol deoxycholic acid per animal).
- alum was 1 to 0.1 ⁇ g per animal, and 80 ⁇ g of OVA protein was used as the antigen.
- the administration liquid was prepared by adding and mixing PBS, alum, and antigen in order of the dosage to a dispersion (solution) of a pH sensitive carrier. The dose was 100 ⁇ L per animal, and the route of administration was subcutaneous. Induction of cellular immunity was evaluated according to the ELIspot method described above.
- the mixture of the antigen and aluminum phosphate and the antigen and potassium aluminum sulfate showed almost no spot formation and could not induce cellular immunity (FIGS. 7A and 7D).
- the vaccine composition using 1 ⁇ g of aluminum phosphate more spots were formed than the mixture of antigen and aluminum phosphate, and cellular immunity was induced (FIG. 7B).
- the vaccine composition using 0.1 ⁇ g of aluminum phosphate resulted in the same spot formation as the mixing of antigen and aluminum phosphate, and cellular immunity was not induced (FIG. 7C).
- alum concentration 1 ⁇ g / 100 ⁇ L to 100 ⁇ g / 100 ⁇ L
- the vaccine composition using 1 ⁇ g of potassium aluminum sulfate showed slightly more spot formation than the mixture of antigen and potassium aluminum sulfate, suggesting that cellular immunity was induced (FIG. 7 (E)).
- aluminum hydroxide and aluminum phosphate are particularly useful as components of a vaccine composition that induces cellular immunity in combination with a pH-sensitive carrier.
- a pH-sensitive carrier dispersion (solution) was mixed with alum so that the total amount of the evaluation sample was 100 ⁇ L. After overnight incubation, a dissolution test was performed using a portion (20 ⁇ L) of these evaluation samples. The dissolution test was performed according to the dissolution test described above. As an amount in 100 ⁇ L, the pH sensitive carrier uses a complex of 100 nmol DLPC and 160 nmol deoxycholic acid, and alum uses 10 ⁇ g aluminum hydroxide, aluminum phosphate, potassium aluminum sulfate (alum). did.
- Deoxycholic acid alone has an elution rate of about 1% or less at pH 7.4 and about 15% at pH 5.0.
- a pH-sensitive carrier not mixed with alum is 1% or less at pH 7.4, pH 5 The dissolution rate was about 60% at 0.0 (FIG. 8A). Since the dissolution rate of DLPC alone was 2% or less at pH 5.0 (FIG. 10 (A)), the pH-sensitive carrier surely had an effect of promoting the membrane destruction function.
- pH sensitive carriers mixed with any of alum such as aluminum hydroxide, aluminum phosphate and potassium aluminum sulfate (alum), they hardly cause elution at pH 7.4, and about 60% at pH 5.0. Elution was caused (FIG. 8 (A)).
- the pH-sensitive carrier satisfies the formulas (1) and (2) and certainly has an effect of promoting the membrane destruction function. Further, in any alum, the pH-sensitive carrier mixed with alum showed the same elution rate as the pH-sensitive carrier not mixed with alum at pH 7.4 and 5.0. It became clear that the mixing did not affect the effect of promoting the film breaking function of the pH-sensitive carrier.
- Alum of aluminum hydroxide, aluminum phosphate, potassium aluminum sulfate (alum) is mixed with 100 nmol of DLPC and 160 nmol of deoxycholic acid as a pH sensitive carrier so as to be 0 to 100 ⁇ g (total amount 100 ⁇ L), After overnight incubation, a dissolution test was performed. In addition, since the solution of 100 micrograms potassium aluminum sulfate (alum) became low pH, it did not measure. As a result, in any addition amount of any alum, the elution rate at pH 5.0 showed a value of about 60%, which was not changed from the case where no alum was mixed (FIG. 8 (B)). . Therefore, it was suggested that alum does not affect the effect of promoting the membrane destruction function of the pH-sensitive carrier at any kind and in any addition amount.
- FIG. 9 shows the results of examining the membrane fusion function promoting effect of the pH-sensitive carrier when mixed with various alums.
- the amphiphile was 100 nmol DLPC
- the pH sensitive compound was 160 nmol deoxycholic acid
- the alum was 10 ⁇ g.
- a dispersion (solution) of pH-sensitive carrier and alum were mixed so that the total amount was 100 ⁇ L, and incubated overnight, and then a part of these mixed solutions was evaluated by a membrane fusion test.
- the membrane fusion test was performed according to the membrane fusion test described above.
- the pH-sensitive carrier showed a fusion rate of about 70% at pH 5.0 when any alum was mixed, and the result satisfied the formula (3) (FIG. 9). That is, the pH-sensitive carrier mixed with alum surely had a membrane fusion function promoting effect. Moreover, in any alum, the pH-sensitive carrier mixed with alum showed the same fusion rate as the pH-sensitive carrier not mixed with alum at pH 7.4 and 5.0 (FIG. 9). Therefore, it was confirmed that mixing with alum does not affect the membrane fusion function promoting effect of the pH-sensitive carrier.
- the pH-sensitive carrier showed the same effect of promoting the membrane disruption function and the membrane fusion function regardless of the mixing with alum, so that the mixing with alum should not affect the function of the pH-sensitive carrier. Became clear.
- the pH-sensitive carrier mixed with alum had an elution rate equivalent to that not mixed with alum in any amount of deoxycholic acid (FIGS. 10A and 10B). That is, it was shown that the mixing of alum with 100 nmol DLPC and 10-640 nmol pH-sensitive carrier, which is a pH-sensitive compound, does not affect the function. It was suggested that in any pH sensitive carrier, which is the amount of any pH sensitive compound, mixing of alum does not affect function.
- the pH-sensitive carrier mixed with alum satisfies the formulas (1) and (2) regardless of the amount of the pH-sensitive compound in the range of 10 to 640 nmol, and certainly has an effect of promoting the membrane destruction function. I did it.
- These pH-sensitive carriers are considered to induce cellular immunity by mixing with alum.
- any pH-sensitive carrier prepared using any pH-sensitive compound those mixed with alum showed an equivalent elution rate compared to those not mixed with alum (Table 1, pH 7.4, and pH 5.0).
- any pH sensitive compound mixing with alum was confirmed not to affect the function of the pH sensitive carrier.
- the pH-sensitive carrier mixed with alum satisfies the formulas (1) and (2) regardless of the pH-sensitive compound, and certainly has an effect of promoting the membrane destruction function. Therefore, these pH-sensitive carriers are considered to induce cellular immunity by mixing with alum (Table 1).
- any pH-sensitive carrier prepared using any amphiphile those mixed with alum showed elution rates equal to or higher than those not mixed with alum (Tables 2-2 and Tables). 2-3).
- the elution rate with deoxycholic acid (pH sensitive compound) alone was about 1% or less at pH 7.4 and about 15% at pH 5.0.
- the pH-sensitive carrier mixed with alum satisfies the formulas (1) and (2) regardless of which amphiphile is used, and certainly has an effect of promoting the membrane destruction function. . Therefore, these pH-sensitive carriers are considered to induce cellular immunity by mixing with alum (Tables 2-2 and 2-3).
- Alum used aluminum hydroxide and the pH sensitive carrier used a complex of DLPC and deoxycholic acid (100 nmol DLPC and 160 nmol deoxycholic acid).
- the dose per animal was set to 100 ⁇ L, and a pH-sensitive carrier containing 10 ⁇ g of alum, 80 ⁇ g of OVA, and 100 nmol of DLPC was administered.
- the dose per animal was 20 ⁇ L, and a pH sensitive carrier containing 2 ⁇ g of alum, 16 ⁇ g of OVA, and 20 nmol of DLPC was administered.
- the dose described above was prepared by using the administration solution used for subcutaneous administration and changing the dose from 100 ⁇ L to 20 ⁇ L. Induction of cellular immunity was evaluated according to the ELIspot method described above.
- the combined use of alum and a pH-sensitive carrier in intradermal administration formed a larger number of spots compared to alum alone (FIGS. 11C and 11D). It was confirmed that the vaccine composition induces cellular immunity even in the intradermal route of administration. Moreover, when the obtained results were compared with subcutaneous administration, the intradermal administration of the vaccine composition formed a larger number of spots than the subcutaneous administration of the vaccine composition despite the small dose (FIG. 11). (B) (D)). It was revealed that the effect of inducing cellular immunity of the vaccine composition is further enhanced by intradermal administration.
- the antigen specificity of the induced cellular immunity was evaluated.
- the evaluation was performed according to the above-described ELIspot method in which no re-stimulation was applied.
- intradermal administration of the vaccine composition did not form a spot (FIG. 11 (H)).
- the cellular immunity induced by intradermal administration of the vaccine composition was found to be antigen specific.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
(2)前記アルミニウムを含有する物質が、水酸化アルミニウム、およびリン酸アルミニウムからなる群より選択される1種以上である、(1)に記載のアジュバント組成物;
(3)前記pH感受性担体が、デオキシコール酸、コール酸、ウルソデオキシコール酸、ケノデオキシコール酸、ヒオデオキシコール酸、高級胆汁酸、グリコデオキシコール酸、グリチルリチン酸、グリチルレチン酸およびそれらの塩からなる群より選択される少なくとも1種のpH感受性化合物と、
炭素数10~12のアシル基のみを有するホスファチジルコリン、炭素数12~18のアシル基を有するポリオキシエチレンソルビタンモノ脂肪酸エステル、炭素数16~18のアシル基のみを有するソルビタン脂肪酸エステル、モノオレイン酸グリセロール、ジラウリン酸グリセロール、ジステアリン酸グリセロール、ジオレイン酸グリセロール、ポリオキシエチレンヒマシ油およびα-トコフェロールからなる群より選択される少なくとも1種の両親媒性物質と、
を含み、膜破壊機能促進効果を発現する、(1)または(2)に記載のアジュバント組成物;
(4)前記アルミニウムを含有する物質が、前記両親媒性物質100nmolに対して、アルミニウム金属換算で1~1000μgで含有される、(3)に記載のアジュバント組成物;
(5)前記pH感受性化合物が、前記両親媒性物質100molに対して10mol以上の割合で含有される、(3)または(4)に記載のアジュバント組成物;
(6)(1)または(2)に記載のアジュバント組成物および抗原を含む、ワクチン組成物;
(7)(3)~(5)のいずれかに記載のアジュバント組成物および抗原を含む、ワクチン組成物;
(8)前記抗原の含有量が、前記両親媒性物質100nmolに対して、3.2~400μgである、(7)に記載のワクチン組成物;
(9)前記抗原がペプチドまたはタンパク質である、(6)~(8)のいずれかに記載のワクチン組成物;
(10)デオキシコール酸、コール酸、ウルソデオキシコール酸、ケノデオキシコール酸、ヒオデオキシコール酸、高級胆汁酸、グリコデオキシコール酸、グリチルリチン酸、グリチルレチン酸およびそれらの塩からなる群より選択される少なくとも1種のpH感受性化合物と、
炭素数10~12のアシル基のみを有するホスファチジルコリン、炭素数12~18のアシル基を有するポリオキシエチレンソルビタンモノ脂肪酸エステル、炭素数16~18のアシル基のみを有するソルビタン脂肪酸エステル、モノオレイン酸グリセロール、ジラウリン酸グリセロール、ジステアリン酸グリセロール、ジオレイン酸グリセロール、ポリオキシエチレンヒマシ油およびα-トコフェロールからなる群より選択される少なくとも1種の両親媒性物質と、
アルミニウムを含有する物質と、
を会合させる工程を含む、アジュバント組成物の製造方法;
(11)デオキシコール酸、コール酸、ウルソデオキシコール酸、ケノデオキシコール酸、ヒオデオキシコール酸、高級胆汁酸、グリコデオキシコール酸、グリチルリチン酸、グリチルレチン酸およびそれらの塩からなる群より選択される少なくとも1種のpH感受性化合物と、
炭素数10~12のアシル基のみを有するホスファチジルコリン、炭素数12~18のアシル基を有するポリオキシエチレンソルビタンモノ脂肪酸エステル、炭素数16~18のアシル基のみを有するソルビタン脂肪酸エステル、モノオレイン酸グリセロール、ジラウリン酸グリセロール、ジステアリン酸グリセロール、ジオレイン酸グリセロール、ポリオキシエチレンヒマシ油およびα-トコフェロールからなる群より選択される少なくとも1種の両親媒性物質と、
アルミニウムを含有する物質と、
を会合させる工程;および
前記会合により得られた会合体に抗原を混合する工程を含む、ワクチン組成物の製造方法。
本形態に係るアジュバント組成物は、pH感受性担体(以下、単に「担体」、「会合体」、または「複合体」と称することがある)と、アルミニウムを含有する物質と、を含む。すなわち、本形態のアジュバント組成物は、自然免疫を活性化する刺激を有する物質(自然免疫を活性化する物質)として、アルミニウムを含有する物質を含むものである。
pH感受性担体は、pHに感受性を有し、pHが酸性になると細胞内の抗原を細胞質基質に輸送できる機能を有する。
pH感受性担体は、生理的pH以上において、pH感受性化合物と両親媒性物質とが会合して形成されているものと考えられる。より詳細には、pH感受性担体は、pH感受性化合物が、両親媒性物質を構成する疎水性部分に会合して形成されているものと考えられる。なお、pH感受性担体の当該会合形式は推測であり、pH感受性担体は、当該会合形式には限定されない。
「膜破壊機能」とは、溶出性試験において溶出を起こす機能を意味する。ここで、本明細書における溶出性試験とは、消光物質と蛍光物質とを含む水溶液を内包したリポソーム(分散液)と、評価サンプル分散液とを、所定のpHに調整した水溶液に添加し、当該水溶液を37℃で90分間あるいは30分間インキュベーションした後、当該水溶液の蛍光強度を測定する試験である。当該方法により、リポソームから溶出した蛍光物質量を測定することができ、pH感受性担体の膜破壊機能を確認することができる。なお、溶出性試験については、後述する実施例で詳細に説明する。
pH感受性化合物は、上記のように、デオキシコール酸、コール酸、ウルソデオキシコール酸、ケノデオキシコール酸、ヒオデオキシコール酸、高級胆汁酸、グリコデオキシコール酸、グリチルリチン酸、グリチルレチン酸およびそれらの塩からなる群から選択される少なくとも1種であることが好ましい。上記「それらの塩」としては、特に制限されないが、リチウム、ナトリウム、カリウム等のアルカリ金属塩;マグネシウム、カルシウム、バリウム等のアルカリ土類金属塩;アンモニウム塩などが挙げられる。これらのpH感受性化合物は、単独で用いても、2種以上を併用してもよい。
両親媒性物質は、上記のように、炭素数10~12のアシル基のみを有するホスファチジルコリン、炭素数12~18のアシル基を有するポリオキシエチレンソルビタンモノ脂肪酸エステル、炭素数16~18のアシル基のみを有するソルビタン脂肪酸エステル、モノオレイン酸グリセロール、ジラウリン酸グリセロール、ジステアリン酸グリセロール、ジオレイン酸グリセロール、ポリオキシエチレンヒマシ油およびα-トコフェロールからなる群より選択される少なくとも1種であることが好ましい。これらの両親媒性物質は、単独で用いても、2種以上を併用してもよい。
pH感受性担体は、pH感受性化合物と両親媒性物質との組み合わせにより、所望のpHにおいて、膜破壊機能促進効果を発現させることができる。この際、pH感受性化合物と両親媒性物質との組み合わせにより、pH感受性担体の膜破壊機能促進効果を発現し始めるpHは異なる。これはpH感受性化合物によってpKaが異なること、さらには両親媒性物質との会合形成の様式が、pH感受性化合物と両親媒性物質との組み合わせにより異なることに由来するものと考えられる。したがって、pH感受性化合物と両親媒性物質との組み合わせを適宜変更することによって、機能を発現するpHを選択することが可能であり、デリバリーを詳細に設定することが可能であるといえる。
本発明のアジュバント組成物は、上述した両親媒性物質およびpH感受性化合物から構成されるpH感受性担体と、自然免疫を活性化する刺激を有する物質(以下、「自然免疫を活性化する物質」と称する。)としてアルミニウムを含有する物質と、を含む。
アジュバント組成物は、水性溶媒(以下、「水性媒体」と称する場合もある。)を含んでいてもよい。
アジュバント組成物は、他の成分を含んでいてもよい。当該他の成分としては、特に制限されないが、安定化剤等が挙げられる。
ワクチン組成物は、アジュバント組成物および抗原を含む。
アジュバント組成物としては、上述したものが用いられうることからここでは説明を省略する。
抗原としては、免疫応答を生じさせるものであれば特に制限されないが、ペプチドまたはタンパク質であることが好ましい。
ワクチン組成物は、他の医薬品添加剤を含んでいてもよい。
ヒドロキシプロピルメチルセルロースなど)、崩壊剤(例えば馬鈴薯澱粉のようなデンプン類、カルボキシメチルセルロースのようなセルロース類、架橋ポリビニルピロリドンなど)、着色剤、矯味矯臭剤などを含みうる。
本形態のワクチン組成物は、対象者に投与されると、ワクチン組成物の外部環境が生理的pH未満(例えば、pH6.5)となったときに、膜破壊機能促進効果、または膜破壊機能促進効果および膜融合機能促進効果を発現し、抗原を効率よく細胞質基質に放出させることが可能になる。そして、好適に細胞性免疫を誘導することができ、免疫を付与することができる。
本発明に係るアジュバント組成物は、特に制限されず、種々の方法により製造することができる。
本発明に係るワクチン組成物の製造方法は、特に制限されず、種々の方法により製造することができる。一実施形態に係るワクチン組成物の製造方法は、デオキシコール酸、コール酸、ウルソデオキシコール酸、ケノデオキシコール酸、ヒオデオキシコール酸、高級胆汁酸、グリコデオキシコール酸、グリチルリチン酸、グリチルレチン酸およびそれらの塩からなる群より選択される少なくとも1種のpH感受性化合物と、炭素数10~12のアシル基のみを有するホスファチジルコリン、炭素数12~18のアシル基を有するポリオキシエチレンソルビタンモノ脂肪酸エステル、炭素数16~18のアシル基のみを有するソルビタン脂肪酸エステル、モノオレイン酸グリセロール、ジラウリン酸グリセロール、ジステアリン酸グリセロール、ジオレイン酸グリセロール、ポリオキシエチレンヒマシ油およびα-トコフェロールからなる群より選択される少なくとも1種の両親媒性物質と、アルミニウムを含有する物質と、を会合させる工程;および前記会合により得られた会合体に抗原を混合する工程を含む。
前記pH感受性化合物を含む溶液は、pH感受性化合物および溶媒を含む。また、必要に応じて添加剤を含んでいてもよい。
前記両親媒性物質を含む溶液は、両親媒性物質および溶媒を含む。また、必要に応じて添加剤を含んでいてもよい。
前記アルミニウムを含有する物質を含む溶液は、アルミニウムを含有する物質および溶媒を含む。また、必要に応じて添加剤を含んでいてもよい。
前記抗原を含む溶液は、抗原および溶媒を含む。
上述のpH感受性化合物を含む水性溶液、両親媒性物質を含む水性溶液、アルミニウムを含有する物質を含む水性溶液、および抗原を含む水性溶液の混合方法は特に制限されない。
実施例では、下記の化合物を用いた。試薬名と製品名が同一の場合は製品名を省略した。
・デオキシコール酸ナトリウム(ナカライテスク社製)
・コール酸ナトリウム(ナカライテスク社製)
・ウルソデオキシコール酸ナトリウム(東京化成工業社製)
・ケノデオキシコール酸(東京化成工業社製)
・ヒオデオキシコール酸(東京化成工業社製)
・グリコデオキシコール酸ナトリウム(ナカライテスク社製)
・グリチルリチン酸モノアンモニウム(東京化成工業社製)
・EYPC(未水添卵黄ホスファチジルコリン:日油社製、COATSOME NC-50)
・DDPC(1,2-ジデカノイル-sn-グリセロ-3-ホスファチジルコリン:日油社製、COATSOME MC-1010)
・DLPC(1,2-ジラウロイル-sn-グリセロ-3-ホスファチジルコリン:日油社製、COATSOME MC-1212)
・ポリオキシエチレンソルビタンモノ脂肪酸エステル(Tween20,80:東京化成工業社製)
・ソルビタン脂肪酸エステル(SPAN80:ナカライテスク社製-ソルビタンモノオレエート)
・ポリオキシエチレンヒマシ油(和光純薬工業社製、ポリオキシエチレン10ヒマシ油)・トコフェロール(ナカライテスク社製、DL-α-トコフェロール)
(2)自然免疫を活性化する刺激を有する物質等
・CpG-DNA(CpG-ODN:InvivoGen社製、ODN-2395)
・酢酸トコフェロール(酢酸DL-α-トコフェロール:ナカライテスク社製)
・水酸化アルミニウム(InvivoGen社製、Alhydrogel 2%)
・リン酸アルミニウム(Alpha Diagnostic Internatiaonal社製、Adjuphos)
・硫酸カリウムアルミニウム(InvivoGen社製、alum crystals)
(3)溶媒等
・注射用水:(大塚製薬株式会社製)
・MES-Na(メルク社製)
・塩化ナトリウム(関東化学社製)
・PBS Tabltes(Phosphate buffered saline:タカラバイオ社製)
・メタノール(ナカライテスク社製)
・エタノール(関東化学社製)
・クロロホルム(和光純薬工業社製)
・水酸化ナトリウム水溶液(0.1mol/L:ナカライテスク社製)
・塩酸(0.1mol/L、1mol/L:ナカライテスク社製)
・OVAペプチド:SIINFEKL(ピーエイチジャパン委託合成)(以下、単に「ペプチド」とも称する。)
・OVAタンパク質(Ovalbumin:和光純薬工業社製、オボアルブミン低エンドトキシン)(以下、単に「OVA」とも称する。)
(4)培地等
・RPMI(ナカライテスク社製、RPMI 1640培地(液体))
・Penicillin-Streptamycin Mixed Solution(ナカライテスク社製)
・FBS(Fetal Bovine Serum,Centified,Heat Inactivatied,US Origin:Gibco社製)
・RBC lysis buffer(Santa Cruz Biotechnology社製):赤血球溶血バッファー
・HBSS(Habk’s Balanced Salt Solution:ナカライテスク社製)
・D-PBS(Dulbecco’s Phosphate Buffered Saline:ナカライテスク社製)
(5)その他試薬
・リン脂質C-テストワコー(和光純薬工業株式会社製)
・Pyranine(東京化成工業社製)
・DPX(p-xylene-bis-pyridinium bromide:Molecular probes社製)
・Triton-X100(和光純薬工業社製)
・NBD-PE(1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine-N(7-nitro-2-1,3-benzoxadiazol-4-yl)ammonium:AvAnti polar lipids社製)・Rh-PE(1,2-Dioleoyl-sn-glycero-3-phosphoehanolamine-N-(lissamine rhodamine B sulfonyl)ammonium:AvAnti polar lipids社製):蛍光標識脂質
・Mouse IFNγ ELISPOT Set(BD バイオサイエンス社製)
・AEC Substrate Set(BD バイオサイエンス社製)
・炭酸水素ナトリウム(和光純薬工業社製)
・炭酸ナトリウム(和光純薬工業社製)
・二次抗体(anti-mouse IgG HRP conjugate、R&D system社製)
・アルブミン(Albumin from bovine serum、Sigma社製)
・ペルオキシダーゼ用発色キット(住友ベークライト株式会社製)
(6)動物
雌、C57BL/6Nマウス(6-8週齢)は日本エスエルシーより購入した。実験はテルモ株式会社における動物実験に関する指針に従って実施した。
超音波照射装置:USC-J
分光光度計:FP-6500
UV-vis分光光度計:UV-3600
CO2、インキュベーター:MCO20AIC
<細胞の培養>
細胞の培養は、5%CO2、37℃に設定したインキュベーター(MCO20AIC)を用いて実施した。
(MES Buffer)
MES:25mM、NaCl:125mMの配合量で調製した。MES Bufferは、特別な記載のない限りpHは7.4である。
(PBS)
PBSは、10錠のPBS Tabltes(タカラバイオ社製)を、1000mLの蒸留水に溶解させ、調製した。なお、pHは、7.35~7.65である。あるいは、購入したD-PBSをPBSとして使用した。
(RPMIメディウム)
抗生物質としてペニシリン(100unit/mL)およびストレプトマイシン(100mg/mL)を添加した。また、必要に応じてFBSを追加で添加し、10%血清含有RPMIメディウムとした。
(自然免疫を刺激する物質の候補(以下、候補物質とも表記)の一次溶液)
・トコフェロールの一次溶液
10mgのトコフェロールを秤量し、1.0mLのエタノールに溶解させた。さらに、PBSにて10倍に希釈し、トコフェロールの一次溶液を調製した。
・酢酸トコフェロールの一次溶液
10mgの酢酸トコフェロールを秤量し、1.0mLのエタノールに溶解させた。さらに、PBSにて10倍に希釈し、酢酸トコフェロールの一次溶液を調製した。
・alumの一次溶液
alumとしては、水酸化アルミニウム、リン酸アルミニウム、硫酸カリウムアルミニウム(ミョウバン)を使用した。
バンガム法による製造
メタノール(またはクロロホルム)に溶解した1000nmolの両親媒性物質と、メタノール(またはクロロホルム)に溶解したpH感受性化合物を、10mLナスフラスコ混合し、溶媒を揮発させて薄膜とした。作製した薄膜に0.5mLのMES Buffer(溶出性試験および膜融合試験の場合)または0.5mLのPBS(マウスへの免疫の場合)を添加し、超音波照射装置を用いて分散させ、pH感受性担体の分散液(溶液)を調製した。また、使用時には、全量を考慮して、MES BufferあるいはPBSにて希釈した。
所定量のpH感受性化合物を秤量し、MES BufferあるいはPBSに溶解させ、pH感受性化合物の溶液を調製した。次に、所定量の両親媒性物質を秤量し、先に調製したpH感受性化合物に溶液に添加し、混合することで、pH感受性担体の分散液(溶液)を調製した。操作は、室温にて実施した。具体的には、1000nmolのDLPCに対して、1600nmolのデオキシコール酸から成るpH感受性担体の場合、13.8mgのデオキシコール酸ナトリウム一水和物を秤量し、10mLのMES BufferあるいはPBSに溶解させた。次に、12.4mgのDLPCを秤量し、先に調製したデオキシコール酸の溶液に添加し、混合することで、pH感受性担体の分散液(溶液)を調製した。また、使用時には、全量を考慮して、MES BufferあるいはPBSにて希釈した。
調製したpH感受性担体の分散液(溶液)に、自然免疫を刺激する物質の候補(以下、候補物質とも表記)の一次溶液を添加し、混合した。濃度を調製するための追加のMES
BufferあるいはPBSを添加し、混合することで、アジュバント組成物を調製した。
比較試料として、抗原のみ、抗原と候補物質の混合(候補物質単独とも表記)、を調製した。また、溶出性試験においては、両親媒性物質単独の分散液、pH感受性担体単独の分散液も調製した。
(溶出性試験:Leakage(溶出率)の測定)
Leakage(溶出率)は、K.Kono et al. Bioconjugate Chem. 2008 19 1040-1048に記載の方法に従い、蛍光物質であるPyranineと消光剤であるDPXとを内包したEYPCリポソームを用いて評価した。
Fusion(膜融合)は、K.Kono et al.Biomaterials 2008 29 4029-4036に記載の方法に従い、FRET(Fluorescence Resonance Energy Transfer)を利用して評価した。蛍光標識は、NBD-PE、Rh-PEを用いた。
投与は麻酔下にて実施した。皮下投与の場合は、背部1箇所に100μL/headにて皮下注射した。alumの投与量は0~100μg/headとし、自然免疫を刺激する物質の候補は10μg/headとした。pH感受性担体は、両親媒性物質:100nmol/head、pH感受性化合物:10~640nmol/headを、基本の投与濃度とし、一部、希釈した条件にて投与を行った。抗原は、OVAタンパク質、あるいはOVAペプチドを使用し、80μg/headとした。また、皮内投与の場合は、皮下投与と同様の投与液を用いて、背部1箇所に20μL/headにて皮内注射した。細胞性免疫を評価する場合は、投与を1回とし、投与から7日後にアッセイを実施した。液性免疫を評価する場合は、投与を2回とし、初回投与から14日後に2回目の投与を行った。さらに、2回目の投与から14日後にアッセイを実施した。
最終の投与から7日目においてマウスを安楽死させ、脾臓を摘出した。3.0mLの10%血清含有RPMIメディウムを添加した後、BD Falconセルストレーナーを用いて脾臓を処理し、細胞懸濁液とした。RBC lysis bufferを用いて溶血操作を行った後、10%血清含有RPMIメディウムを用いて細胞を洗浄した。細胞を10%血清含有RPMIメディウムにて分散した後、細胞数をカウントし、脾臓の細胞分散液を得た。
ELIspot法は、Mouse IFNγ ELISPOT Setを用いて実施した。細胞を播種する前日に、96well ELIspotプレートにキットに付属のdetection antibodyを吸着させて、プレートを作製した。作製したプレートを10%血清含有RPMIメディウムにて洗浄した後、200μLの10%血清含有RPMIメディウムを添加し、37℃にて2時間静置しブロッキングを行った。10%血清含有RPMIメディウムにてプレートを洗浄した後、抗原の再刺激を加える場合は、40μg/mLのOVAペプチドを含む10%血清含有RPMIメディウム100μLをプレートに添加し、抗原の再刺激を加えない場合は10%血清含有RPMIメディウム100μLをプレートに添加した。前記プレートに、脾臓の細胞分散液を所定の細胞数となるように播種し、最後に、10%血清含有RPMIメディウムを用いて1穴あたりの全量が200μLとなるように、調整した。その後、二晩培養し、プレートの呈色を行った。
2回目の投与を行う前日に部分採血を行い、1回投与の抗体価を調べた。また、2回目の投与から14日後に採血を行い、2回投与の抗体価を調べた。採血した血液を室温にて2時間静置し、遠心分離することにより血清を得た。500mLのPBSに5gのアルブミンを溶解し、Block bufferとした。1.47gの炭酸水素ナトリウムと0.80gの炭酸ナトリウムを500mLの水に溶解させ、Coating Bufferとした。プレートの洗浄には、500mLのPBSに2.5mLのTween20を添加したものを使用した。
前記記載の方法に従って調製した分散液を用いて各種評価を行った。
pH感受性担体と併用し、細胞性免疫を誘導する高い効果を有する、自然免疫を活性化する物質の選定を行った。入手性および注射実績を考慮して、トコフェロール、酢酸トコフェロール、alum(水酸化アルミニウム)を、自然免疫を活性化する物質の候補(以下、候補物質とも表記)とし、pH感受性担体との併用による、細胞性免疫誘導の効果を調べた。
△:コントロールと比べて、わずかに細胞性免疫の誘導が見られる
×:コントロールと同等または同等以下の細胞性免疫の誘導である。
CpG-ODNは特定の塩基配列を有する合成オリゴヌクレオチドであり、細胞性免疫を誘導することが報告されている試薬である。本試薬をポジティブコントロールとして用いることで、alumとpH感受性担体との併用による、細胞性免疫の誘導活性の高さを評価した。CpG-ODNは、1匹あたり10μgを使用し、他の実験条件は全て(1)と同じとした。評価は(1)のELIspotと同一のプレートにて、実施した。
alum(水酸化アルミニウム)は、pH感受性担体との併用し、細胞性免疫を誘導することが明らかとなった。そこで、細胞性免疫を誘導するために必要となるalumの量を調べた。alumは水酸化アルミニウムを使用し、pH感受性担体はDLPCとデオキシコール酸の複合体を使用した(1匹あたり、100nmolのDLPCおよび160nmolのデオキシコール酸)。alumは、1匹あたり100~0.1μgとし、抗原は1匹あたり80μgのOVAタンパク質を使用した。投与液は、pH感受性担体の分散液(溶液)に、投与量を調製するためのPBS、alum、抗原の順に添加し、混合することにより調製した。投与量は、1匹あたり100μLとし、投与経路は皮下とした。細胞性免疫の誘導は、前記記載のELIspot法に従って評価した。なお、alum単独とは、抗原とalumとを混合したものを指す。
次に、細胞性免疫を誘導するために必要な、pH感受性担体の量を調べた。1匹あたり10μgの水酸化アルミニウムを使用し、種々の倍率に希釈したpH感受性担体の分散液を用いて、投与液を調製した。pH感受性担体は、100nmolのDLPCに対して、160nmolのデオキシコール酸である複合体を使用した。その他の条件は(1)および(3)と同様とした。
alumとpH感受性担体との併用による、液性免疫の誘導について検証した。液性免疫の誘導は、IgG抗体価によって評価した。1回あたりの投与量として、alumは10μgの水酸化アルミニウムを使用し、pH感受性担体は100nmolのDLPCと160nmolのデオキシコール酸からなる複合体を使用した。抗原は、80μgのOVAタンパク質とした。投与液は、pH感受性担体の分散液(溶液)に、投与量を調製するためのPBS、alum、抗原の順に添加し、混合することにより調製した。投与量は、1匹あたり100μLとし、投与経路は皮下とした。液性免疫を評価するため、投与は2回行った。抗体価の評価は、前記記載の抗体価の測定に従って実施した。
本明細書中において、alumは、アルミニウムを含有するアジュバントの総称として用いている。alumの種類としては、水酸化アルミニウム、リン酸アルミニウム、硫酸カリウムアルミニウム(ミョウバン)、塩化アルミニウムなどが挙げられ、これらの中から、入手が可能、かつpH感受性担体との併用によって、細胞性免疫の誘導が可能なものを調べた。
(7-1)膜破壊機能促進効果に及ぼす、alumの種類、およびalumの量の影響について
pH感受性担体の膜破壊機能促進効果および膜融合機能促進効果は、細胞のエンドソーム膜を破壊し、クロスプレゼンテーションを促進させるための、重要な機能である。また、alumは種々の物質を吸着させることが知られている。そのため、alumとpH感受性担体とを混合した場合における、pH感受性担体の機能への影響を調べた。
続いて、膜融合機能促進効果に及ぼすalumの影響を調べた。図9は、種々のalumと混合した場合における、pH感受性担体の膜融合機能促進効果を調べた結果である。両親媒性物質は100nmolのDLPCとし、pH感受性化合物は160nmolのデオキシコール酸とし、alumは10μgとした。全量を100μLとなるように、pH感受性担体の分散液(溶液)とalumとを混合し、一晩インキュベートした後、これらの混合溶液の一部を膜融合試験にて評価した。膜融合試験は、前記記載の膜融合試験に従って実施した。
次に、pH感受性担体の組成を変化させた場合における、pH感受性担体の機能に及ぼすalumの影響を調べた。alumとして、10μgの水酸化アルミニウムを使用し、pH感受性担体として、100nmolのDLPCと、種々の量のデオキシコール酸からなる複合体を使用した(全量100μL)。(7-1)と同様に、pH感受性担体の分散液(溶液)とalumとを混合し、一晩インキュベートした後、これらの混合溶液の一部を溶出性試験にて評価した。溶出性試験は、前記記載の溶出性試験に従って実施した。
さらに、種々のpH感受性化合物から構成されるpH感受性担体の機能において、alumの影響を調べた。alumとしては、10μgの水酸化アルミニウムを使用し、pH感受性担体としては、100nmolのDLPCおよび160nmolの種々のpH感受性化合物からなる複合体を使用した(全量100μL)。(7-1)と同様に、pH感受性担体とalumとを混合し、一晩インキュベートした後、これらの混合溶液の一部を溶出性試験にて評価した。溶出性試験は、前記記載の溶出性試験に従って実施した。DLPC(両親媒性物質)単独による溶出率は、pH5.0にて2.0%以下であった。
また、種々の両親媒性物質からなるpH感受性担体の機能において、alumの影響を調べた。alumとしては、10μgの水酸化アルミニウムを使用し、pH感受性担体としては、100nmolの種々の両親媒性物質および160nmolのデオキシコール酸からなる複合体を使用した(全量100μL)。(7-1)と同様に、100nmolの所定の両親媒性物質および160nmolのデオキシコール酸を含むpH感受性担体の分散液(溶液)とalumとを混合し、一晩インキュベートした後、これらの混合溶液の一部を溶出性試験にて評価した。溶出性試験は、前記記載の溶出性試験に従って実施した。
一般的に、皮内には多くの免疫担当細胞が存在しており、皮内にワクチンを接種することで、免疫惹起の亢進や抗原量の削減が可能であることが知られている。そこで、ワクチン組成物を皮内に投与した場合における、細胞性免疫の誘導を確認した。
Claims (11)
- pH感受性担体と、アルミニウムを含有する物質と、を含むアジュバント組成物。
- 前記アルミニウムを含有する物質が、水酸化アルミニウム、およびリン酸アルミニウムからなる群より選択される1種以上である、請求項1に記載のアジュバント組成物。
- 前記pH感受性担体が、デオキシコール酸、コール酸、ウルソデオキシコール酸、ケノデオキシコール酸、ヒオデオキシコール酸、高級胆汁酸、グリコデオキシコール酸、グリチルリチン酸、グリチルレチン酸およびそれらの塩からなる群より選択される少なくとも1種のpH感受性化合物と、
炭素数10~12のアシル基のみを有するホスファチジルコリン、炭素数12~18のアシル基を有するポリオキシエチレンソルビタンモノ脂肪酸エステル、炭素数16~18のアシル基のみを有するソルビタン脂肪酸エステル、モノオレイン酸グリセロール、ジラウリン酸グリセロール、ジステアリン酸グリセロール、ジオレイン酸グリセロール、ポリオキシエチレンヒマシ油およびα-トコフェロールからなる群より選択される少なくとも1種の両親媒性物質と、
を含み、膜破壊機能促進効果を発現する、請求項1または2に記載のアジュバント組成物。 - 前記アルミニウムを含有する物質が、前記両親媒性物質100nmolに対して、アルミニウム金属換算で1~1000μgで含有される、請求項3に記載のアジュバント組成物。
- 前記pH感受性化合物が、前記両親媒性物質100molに対して10mol以上の割合で含有される、請求項3または4に記載のアジュバント組成物。
- 請求項1または2に記載のアジュバント組成物および抗原を含む、ワクチン組成物。
- 請求項3~5のいずれか1項に記載のアジュバント組成物および抗原を含む、ワクチン組成物。
- 前記抗原の含有量が、前記両親媒性物質100nmolに対して、3.2~400μgである、請求項7に記載のワクチン組成物。
- 前記抗原がペプチドまたはタンパク質である、請求項6~8のいずれか1項に記載のワクチン組成物。
- デオキシコール酸、コール酸、ウルソデオキシコール酸、ケノデオキシコール酸、ヒオデオキシコール酸、高級胆汁酸、グリコデオキシコール酸、グリチルリチン酸、グリチルレチン酸およびそれらの塩からなる群より選択される少なくとも1種のpH感受性化合物と、
炭素数10~12のアシル基のみを有するホスファチジルコリン、炭素数12~18のアシル基を有するポリオキシエチレンソルビタンモノ脂肪酸エステル、炭素数16~18のアシル基のみを有するソルビタン脂肪酸エステル、モノオレイン酸グリセロール、ジラウリン酸グリセロール、ジステアリン酸グリセロール、ジオレイン酸グリセロール、ポリオキシエチレンヒマシ油およびα-トコフェロールからなる群より選択される少なくとも1種の両親媒性物質と、
アルミニウムを含有する物質と、
を会合させる工程を含む、アジュバント組成物の製造方法。 - デオキシコール酸、コール酸、ウルソデオキシコール酸、ケノデオキシコール酸、ヒオデオキシコール酸、高級胆汁酸、グリコデオキシコール酸、グリチルリチン酸、グリチルレチン酸およびそれらの塩からなる群より選択される少なくとも1種のpH感受性化合物と、
炭素数10~12のアシル基のみを有するホスファチジルコリン、炭素数12~18のアシル基を有するポリオキシエチレンソルビタンモノ脂肪酸エステル、炭素数16~18のアシル基のみを有するソルビタン脂肪酸エステル、モノオレイン酸グリセロール、ジラウリン酸グリセロール、ジステアリン酸グリセロール、ジオレイン酸グリセロール、ポリオキシエチレンヒマシ油およびα-トコフェロールからなる群より選択される少なくとも1種の両親媒性物質と、
アルミニウムを含有する物質と、
を会合させる工程;および
前記会合により得られた会合体に抗原を混合する工程を含む、ワクチン組成物の製造方法。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017521826A JPWO2016194685A1 (ja) | 2015-06-02 | 2016-05-23 | アルミニウムを含有するアジュバント組成物およびこれを含むワクチン組成物 |
CA2987864A CA2987864C (en) | 2015-06-02 | 2016-05-23 | Adjuvant composition containing aluminum and vaccine composition containing the same |
US15/578,535 US20180153985A1 (en) | 2015-06-02 | 2016-05-23 | Adjuvant composition containing aluminum and vaccine composition containing the same |
EP16803120.1A EP3305320B1 (en) | 2015-06-02 | 2016-05-23 | Aluminum-containing adjuvant composition, and vaccine composition containing same |
AU2016273638A AU2016273638B2 (en) | 2015-06-02 | 2016-05-23 | Adjuvant composition containing aluminum and vaccine composition containing the same |
RU2017146055A RU2721417C2 (ru) | 2015-06-02 | 2016-05-23 | Адъювантная композиция, содержащая алюминий, и содержащая ее вакцинная композиция |
CN201680032101.4A CN107614009A (zh) | 2015-06-02 | 2016-05-23 | 含有铝的佐剂组合物及包含其的疫苗组合物 |
US17/066,172 US20210030867A1 (en) | 2015-06-02 | 2020-10-08 | Adjuvant composition containing aluminum and vaccine composition containing the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015-112519 | 2015-06-02 | ||
JP2015112519 | 2015-06-02 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/578,535 A-371-Of-International US20180153985A1 (en) | 2015-06-02 | 2016-05-23 | Adjuvant composition containing aluminum and vaccine composition containing the same |
US17/066,172 Continuation US20210030867A1 (en) | 2015-06-02 | 2020-10-08 | Adjuvant composition containing aluminum and vaccine composition containing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016194685A1 true WO2016194685A1 (ja) | 2016-12-08 |
Family
ID=57441384
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2016/065216 WO2016194685A1 (ja) | 2015-06-02 | 2016-05-23 | アルミニウムを含有するアジュバント組成物およびこれを含むワクチン組成物 |
Country Status (8)
Country | Link |
---|---|
US (2) | US20180153985A1 (ja) |
EP (1) | EP3305320B1 (ja) |
JP (1) | JPWO2016194685A1 (ja) |
CN (1) | CN107614009A (ja) |
AU (1) | AU2016273638B2 (ja) |
CA (1) | CA2987864C (ja) |
RU (1) | RU2721417C2 (ja) |
WO (1) | WO2016194685A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018207841A1 (ja) | 2017-05-11 | 2018-11-15 | テルモ株式会社 | 複合体、複合体を含むpH感受性組成物、および複合体の製造方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018181542A1 (ja) * | 2017-03-29 | 2018-10-04 | テルモ株式会社 | アジュバント組成物およびこれを含むワクチン組成物並びに薬剤キット |
CN118105473A (zh) * | 2024-04-30 | 2024-05-31 | 成都欧林生物科技股份有限公司 | 一种预防或治疗Hp感染口服免疫原性组合物及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011525190A (ja) * | 2008-06-19 | 2011-09-15 | バリエーション バイオテクノロジーズ インコーポレイティド | インフルエンザを処置するための組成物および方法 |
JP2012532200A (ja) * | 2009-07-06 | 2012-12-13 | ヴァリエーション バイオテクノロジーズ インコーポレイテッド | 小胞を調製する方法及びこれから製造される製剤 |
WO2013180253A1 (ja) * | 2012-05-31 | 2013-12-05 | テルモ株式会社 | pH感受性担体およびその製造方法、並びに該担体を含むpH感受性医薬、pH感受性医薬組成物およびこれを用いた培養方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5100662A (en) * | 1989-08-23 | 1992-03-31 | The Liposome Company, Inc. | Steroidal liposomes exhibiting enhanced stability |
US20040185057A1 (en) * | 2001-06-15 | 2004-09-23 | Kirkby Nikolai Soren | Therapeutical vaccination |
AU2003293942B2 (en) * | 2002-12-20 | 2009-12-10 | Glaxosmithkline Biologicals Sa | HPV-16 and -18 L1 VLP vaccine |
US20110097418A1 (en) * | 2009-05-29 | 2011-04-28 | Variation Biotechnologies, Inc. | Compositions and methods for treating influenza |
CA2828253C (en) * | 2011-02-25 | 2016-10-18 | South Dakota State University | Polymer conjugated protein micelles |
-
2016
- 2016-05-23 JP JP2017521826A patent/JPWO2016194685A1/ja active Pending
- 2016-05-23 AU AU2016273638A patent/AU2016273638B2/en active Active
- 2016-05-23 WO PCT/JP2016/065216 patent/WO2016194685A1/ja active Application Filing
- 2016-05-23 EP EP16803120.1A patent/EP3305320B1/en active Active
- 2016-05-23 RU RU2017146055A patent/RU2721417C2/ru active
- 2016-05-23 CN CN201680032101.4A patent/CN107614009A/zh active Pending
- 2016-05-23 US US15/578,535 patent/US20180153985A1/en not_active Abandoned
- 2016-05-23 CA CA2987864A patent/CA2987864C/en active Active
-
2020
- 2020-10-08 US US17/066,172 patent/US20210030867A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011525190A (ja) * | 2008-06-19 | 2011-09-15 | バリエーション バイオテクノロジーズ インコーポレイティド | インフルエンザを処置するための組成物および方法 |
JP2012532200A (ja) * | 2009-07-06 | 2012-12-13 | ヴァリエーション バイオテクノロジーズ インコーポレイテッド | 小胞を調製する方法及びこれから製造される製剤 |
WO2013180253A1 (ja) * | 2012-05-31 | 2013-12-05 | テルモ株式会社 | pH感受性担体およびその製造方法、並びに該担体を含むpH感受性医薬、pH感受性医薬組成物およびこれを用いた培養方法 |
Non-Patent Citations (8)
Title |
---|
EIJI YUBA ET AL.: "Shinki pH Kanjusei Tantai o Mochiita Peptide Tanpakushitsu no Cytosol Delivery", ANNUAL MEETING OF THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM PROGRAM YOKOSHU, vol. 30, July 2014 (2014-07-01), pages 209, XP009507720 * |
EIJI YUBA: "Antigen delivery using pH-sensitive polymer-modified liposomes and their application to cancer immunotherapy", MAJOR HISTOCOMPATIBILITY COMPLEX (MHC, vol. 20, no. 3, 2013, pages 181 - 189, XP055333747, ISSN: 2186-9995 * |
LEE K.Y. ET AL.: "Investigation of antigen delivery route in vivo and immune-boosting effects mediated by pH-sensitive liposomes encapsulated with K(b)-restricted CTL epitope.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 292, no. 3, 2002, pages 682 - 688, XP055333749, ISSN: 0006-291X * |
RICHARDS R.L. ET AL.: "Liposomes, lipid A, and aluminum hydroxide enhance the immune response to a synthetic malaria sporozoite antigen.", INFECTION AND IMMUNITY, vol. 56, no. 3, 1988, pages 682 - 686, XP008034645, ISSN: 0019-9567 * |
See also references of EP3305320A4 * |
WATARAI S. ET AL.: "Efficiency of pH-sensitive fusogenic polymer-modified liposomes as a vaccine carrier.", SCIENTIFIC WORLD JOURNAL, vol. 2013, 2013, pages 1 - 7, XP055333744, ISSN: 2356-6140 * |
YOSHIZAKI Y. ET AL.: "Potentiation of pH- sensitive polymer-modified liposomes with cationic lipid inclusion as antigen delivery carriers for cancer immunotherapy.", BIOMATERIALS, vol. 35, no. 28, 2014, pages 8186 - 8196, XP028861819, ISSN: 0142-9612 * |
YUBA E. ET AL.: "Dextran derivative-based pH- sensitive liposomes for cancer immunotherapy.", BIOMATERIALS, vol. 35, no. 9, 2014, pages 3091 - 3101, XP028829008, ISSN: 0142-9612 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018207841A1 (ja) | 2017-05-11 | 2018-11-15 | テルモ株式会社 | 複合体、複合体を含むpH感受性組成物、および複合体の製造方法 |
EP3622967A4 (en) * | 2017-05-11 | 2021-02-17 | Terumo Kabushiki Kaisha | COMPOSITE BODY, PH SENSITIVE COMPOSITION CONTAINING THE COMPOSITE BODY, AND PROCESS FOR THE PRODUCTION OF THE COMPOSITE BODY |
Also Published As
Publication number | Publication date |
---|---|
EP3305320A4 (en) | 2019-01-23 |
AU2016273638B2 (en) | 2019-06-06 |
EP3305320A1 (en) | 2018-04-11 |
US20210030867A1 (en) | 2021-02-04 |
EP3305320B1 (en) | 2024-02-07 |
AU2016273638A1 (en) | 2017-12-14 |
CA2987864C (en) | 2020-08-18 |
RU2017146055A (ru) | 2019-07-09 |
CA2987864A1 (en) | 2016-12-08 |
RU2721417C2 (ru) | 2020-05-19 |
US20180153985A1 (en) | 2018-06-07 |
JPWO2016194685A1 (ja) | 2018-03-29 |
RU2017146055A3 (ja) | 2019-07-17 |
CN107614009A (zh) | 2018-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6487850B2 (ja) | アジュバント組成物およびこれを含むワクチン組成物、並びにこれらの製造方法 | |
Chen et al. | A simple but effective cancer vaccine consisting of an antigen and a cationic lipid | |
Nakamura et al. | The nanoparticulation by octaarginine-modified liposome improves α-galactosylceramide-mediated antitumor therapy via systemic administration | |
JP5971945B2 (ja) | カチオン性脂質の鏡像異性体による免疫応答の刺激 | |
US20210030867A1 (en) | Adjuvant composition containing aluminum and vaccine composition containing the same | |
TWI673062B (zh) | 粒狀疫苗調配物 | |
Nakamura et al. | Incorporation of polyinosine–polycytidylic acid enhances cytotoxic T cell activity and antitumor effects by octaarginine-modified liposomes encapsulating antigen, but not by octaarginine-modified antigen complex | |
WO2018181542A1 (ja) | アジュバント組成物およびこれを含むワクチン組成物並びに薬剤キット | |
US20210145750A1 (en) | COMPLEX, pH SENSITIVE COMPOSITION INCLUDING COMPLEX, AND METHOD FOR PRODUCING COMPLEX | |
US20220160867A1 (en) | Methods and compositions comprising cationic lipids for immunotherapy by direct tumor injection | |
Watson et al. | Corrigendum to “Design considerations for liposomal vaccines: Influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens”[Vaccine 30 (13)(2012) 2256–2272] | |
EP2060271A1 (en) | Liposome and immunostimulating composition comprising the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16803120 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017521826 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2987864 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15578535 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2016273638 Country of ref document: AU Date of ref document: 20160523 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2016803120 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017146055 Country of ref document: RU |